 
 
Clinical Investigation Plan Title STOP AF First 
Clinical Investigation Plan Identifier MDT16012AFS001 
Study Product Arctic Front Advanceâ„¢ Card iac CryoAblation Catheter 
Application Number IDE #G1160219 
ClinicalTrials.gov Identifier [STUDY_ID_REMOVED] 
Sponsor Medtronic 
[ADDRESS_657483] Clinical Investigation Plan 
Document Version (Date) 4.0 (10-APR-2017) 
 

056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657484]  Page 1 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  
 
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  STOP AF First  
Clinical Investigation Plan Identifier  MDT16012AFS001  
Study Product Name  [CONTACT_508805]/Local Sponsor  [LOCATION_002] of America  
Medtronic, Inc.  
[ADDRESS_657485] Inclusion Criteria per FDA feedback â€œA 
diagnosis of symptomatic paroxysmal AF with 
the following documentation: (1) physicianâ€™s 
note indicating recurrent self - termina ting AF or 
paroxysmal AF ; and (2) any ECG documented 
AF within 6 months prior to enrollment. â€œ  
Exclusion criteria - changed [ADDRESS_657486]  
Chris Anderson, Sr. Sta tistician 
2.0 Section 11.1, Study Procedures, Schedule of 
Events- Added randomization, treatment arm, 
reablation /crossover ablation requirements, 
pregnancy screen, chest x -ray for phrenic nerve 
injury, MRI or CT scan for suspected PV 
stenosis, health care utilization data collection.  
Changed QOL screening from SF- 12 to EQ -5D.  
Changed Holter to â€œcontinuous ambulato ry ECG 
monitoring.â€  Kirsten Rasmussen, Clinical 
Research Specialist  
Chris Anderson, Sr. Statistician  
2.[ADDRESS_657487]  
Chris Anderson, Sr. Statistician  
2.0 Section 11.5, Study Procedures, Description of All Study Procedures and Visits- Updated per 
Section 11.1, Schedule of Events, added 
antiarrhythmic drug arm requirements, modified 
anticoagulation and TEE requirements, updated 
phrenic nerve injury screening requirements, 
added assessment of whether neurological 
evaluation is required at hospi[INVESTIGATOR_2345], 
changed six week phone/office visit to one 
month office visit and added additional 
requirements to the visit, changed Holter 
requirement to a general term â€œ24 hour 
continuous monitoring,â€ describe the [ADDRESS_657488]  
Chris Anderson, Sr. Statistician  
3.0 Changed â€œObjective Performance Criteriaâ€ to â€œPerformance Goalâ€ in Section 2, Glossary, and 
Sections 15.2.[ADDRESS_657489]  
Chris Anderson, Sr. Statistician  
3.0 Updated the following sections to change the 30 
day AAD optimization period to a 90 day AAD 
optimization period:  3.0, Synopsis, 6.0, Figure 
1, Study Design Table, 11.1, Schedule of Events, 
and [IP_ADDRESS], Primary Efficacy Endpoint, 11.5.8, 
Scheduled Follow -up Visits, 15.1.2, Endpoint 
Definition  Kirsten Rasmussen, Clinical 
Research Specialist  
Chris Anderson, Sr. Statistician  
3.0 Added the following statement to the medication sections:  The 2014 AHA/ACC/HRS Guideline for 
the Management of Patients with Atrial 
Fibrillation should be consulted for AAD 
prescriptions.  (Sections 11.2, 11.5.2, and 
11.5.5) Kirsten Rasmussen, Clinical 
Research Specialist  
Chris Anderson, Sr. Statistician  
4.0 Edited two exclusion crit eria:  1) changed the 
BMI value from >35 to >40; 2) added â€œsevereâ€ prior to obstructive sleep apnea.  Mindy Hoey, Prin. Clinical Research 
Specialist 
Chris Anderson, Sr. Statistician 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657490] Research Organizations  ....................................................................................... 13 
Steering Committee  ............................................................................................................ 13 
2. Glossar y ..................................................................................................................... 14 
3. Synopsis  .................................................................................................................... 17 
4. Introduction  .............................................................................................................. 23 
4.1.  Background  ................................................................................................................. 23 
4.2.  Purpose  ........................................................................................................................ 24 
5. Objectives and Endpoints  ......................................................................................... 25 
5.1.  Objectives  ................................................................................................................... 25 
5.1.1.  Primary Objective(s)  ........................................................................................................... 25 
[IP_ADDRESS].  Primary Efficacy Objective  ............................................................................................. 25 
[IP_ADDRESS].  Primary Safety Objective  ................................................................................................ 25 
5.1.2.  Secondary Objectives  ......................................................................................................... 25 
  
5.1.4.  Primary Endpoint  ................................................................................................................. 26 
[IP_ADDRESS].  Primary Efficacy Endpoint  .............................................................................................. [ADDRESS_657491] Description  .................................................................................................. 33 
7.1.  General ......................................................................................................................... 33 
7.2.  Arcti
c Front Advanceâ„¢ Cardiac CryoAblation Catheters  ................................... 35 
7.3.  Freezor Â® MAX Cardiac CryoAblation Catheters  ................................................. [ADDRESS_657492]  Page 6 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 7.4.  FlexCath Advanceâ„¢ Steerable Sheath  .................................................................. 36 
7.5.  Achieveâ„¢ or Achieve Advanceâ„¢ Mappi[INVESTIGATOR_54370]  ........................................... [ADDRESS_657493] Training Requirements  ............................................................................. 39 
7.12.  Packaging  .................................................................................................................... 39 
7.13.  Investigational Device Storage, Handling and Traceability  ............................. 39 
8. Investigator/Investigator Center Selection  ................................................................ [ADDRESS_657494] Consent  ......................................................................................................... 48 
11.4.  Randomization and Treatment Assignment  ........................................................ 50 
11.5.  Description of All Study Procedures and Visits  ................................................... 50 
11.5.1.  Enrollment & Baseline  ..................................................................................................... 50 
11.5.2.  Control Arm - AAD Initiation  ........................................................................................... 51 
11.5.3.  Treatment Arm- Cryoablation Procedure  ..................................................................... 52 
[IP_ADDRESS].  Esophageal Visualization and Temperature Monitoring  ......................................... 52 
11.
5.3.2.  Pre-procedure Anticoagulation  .................................................................................. 52 
[IP_ADDRESS].  Intra-procedure Anticoagulation  ............................................................................... 52 
[IP_ADDRESS].  Post-procedure Anticoagulation ................................................................................. 52 
[IP_ADDRESS].  Diaphragm Movement  ................................................................................................. 53 
[IP_ADDRESS].  Balloon Pulmonary Vein (PV) Cryoablation  .............................................................. 53 
[IP_ADDRESS].  Other Ablations During Index Procedure  ................................................................. 54 
[IP_ADDRESS].  Cardioversion  ................................................................................................................ 54 
[IP_ADDRESS].  Procedure Documentation  .......................................................................................... [ADDRESS_657495]  Page 7 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  One Month Office Visit  ................................................................................................ 57 
[IP_ADDRESS].  Three Month Office Visit  ............................................................................................. 58 
[IP_ADDRESS].  Six Month Office Visit  .................................................................................................. 58 
[IP_ADDRESS].  Twelve month Office Visit  .......................................................................................... 59 
11.5.9.  Unscheduled Office Visits  ............................................................................................... 60 
11.5.10.  Re-Ablation/Crossover Ablation  ................................................................................. [ADDRESS_657496] Withdrawal or Discontinuation  ............................................................ 63 
12. Risks and Benefits  ..................................................................................................... 65 
12.1.  Potential Risks  ........................................................................................................... 65 
12.2.  Risk Minimization  ...................................................................................................... 68 
12.3.  Potential Benefits  ...................................................................................................... 68 
12.4.  Risk-Benefit Rationale ..............................................................................................  68 
13. Adverse Event Assessments ....................................................................................... 69 
13.1.  Definitions/Classifications  ...................................................................................... [ADDRESS_657497] Death  .................................................................................................................. 77 
[IP_ADDRESS].  Death Data Collection  ................................................................................................. 77 
[IP_ADDRESS].  Death Classification and Reporting  ........................................................................... [ADDRESS_657498] Complaints  ......................................................................................................... 78 
14. Data Review Committees  .......................................................................................... 80 
15. Statistical Design and Methods  ................................................................................. 81  
15.1.  Primary Efficacy Objective  ...................................................................................... 82 
15.1.1.  Hypothesis  ........................................................................................................................ 82 
15.1.2.  Endpoint Definition  .......................................................................................................... 82 
15.1.3.  Performance Requirements  ........................................................................................... 83 
15.1.4.  Rationale for performance criteria ................................................................................ 83 
15.1.5.  Analysis Methods  ............................................................................................................. 83 
15.1.6.  Sample Size ...................................................................................................................... 84 
15.1.7.  Determination of Patients/Data for Analysis  ............................................................... [ADDRESS_657499]  Page 8 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 15.2.1.  Hypothesis  ........................................................................................................................ 85 
15.2.2.  Endpoint Definition  .......................................................................................................... 85 
15.2.3.  Performance requirements  ............................................................................................ 85 
15.2.4.  Rationale for Performance Criteria ............................................................................... 85 
15.2.5.  Analysis Methods  ............................................................................................................. 86 
15.2.6.  Sample Size ...................................................................................................................... 86 
15.2.7.  Determination of Patients/Data for Analysis  ............................................................... [ADDRESS_657500] on Quality -of-Life (AFEQT) .................................................... 88 
[IP_ADDRESS].  Hypothesis  .................................................................................................................... 88 
[IP_ADDRESS].  Endpoint Definition  ...................................................................................................... 89 
[IP_ADDRESS].  Analysis Methods  ......................................................................................................... 89 
[IP_ADDRESS].  Performance Criteria ................................................................................................... 89 
[IP_ADDRESS].  Rationale for Performance Criteria ............................................................................ 89 
[IP_ADDRESS].  Determination of Subjects/Data for Analysis  ........................................................... 89 
[IP_ADDRESS].  Additional analyses  ...................................................................................................... 89 
15.3.2.  EQ-5D Questionnaire  ...................................................................................................... 90 
[IP_ADDRESS].  Hypothesis  .................................................................................................................... 90 
[IP_ADDRESS].  Endpoint Definition  ...................................................................................................... 90 
15
.3.2.3.  Analysis Methods  ......................................................................................................... 90 
[IP_ADDRESS].  Performance criteria  .................................................................................................... 90 
[IP_ADDRESS].  Rationale for Performance Criteria ............................................................................ 90 
[IP_ADDRESS].  Determination of Subjects/Data for Analysis  ........................................................... 90 
15.3.3.  Cardiovascular hospi[INVESTIGATOR_602], ED and unscheduled office visits  .......................... 91 
[IP_ADDRESS].  Hypothesis  .................................................................................................................... 91 
[IP_ADDRESS].  Endpoint Definition  ...................................................................................................... 91 
[IP_ADDRESS].  Analysis Methods  ......................................................................................................... 91 
[IP_ADDRESS].  Performance Requirements  ........................................................................................ 91 
[IP_ADDRESS].  Ratio
nale for Performance Requirements  ................................................................ 91 
[IP_ADDRESS].  Determination of Subjects/Data for Analysis  ........................................................... 92 
15.3.4.  Cardioversions .................................................................................................................. 92 
[IP_ADDRESS].  Hypothesis  .................................................................................................................... 92 
[IP_ADDRESS].  Endpoint Definition  ...................................................................................................... 92 
[IP_ADDRESS].  Analysis Methods  ......................................................................................................... 92 
[IP_ADDRESS].  Performance Requirements  ........................................................................................ 92 
[IP_ADDRESS].  Rationale for Performance Criteria ............................................................................ 93 
[IP_ADDRESS].  Determination of Subjects/Data for Analysis  ........................................................... [ADDRESS_657501]  Page 9 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
    
  
  
  
   
  
   
   
   
  
   
   
   
  
  
   
16. Ethics  ........................................................................................................................ 98 
16.1.  Statement(s)  of Compliance  ................................................................................... [ADDRESS_657502] Access to Source Data/Documents  ......................................................... [ADDRESS_657503] Retention and Reports  ............................................................................. 101 
17.7.1.  Investigator Records  ..................................................................................................... 102 
17.7.2.  Investigator Reports  ..................................................................................................... 102 
17.7.3.  Sponsor Records  ............................................................................................................ 105 
17.7.4.  Sponsor Reports  ............................................................................................................ 106 
17.8.  Publication and Use of Information  .................................................................... 110 
17.8.1.  Management of Primary, Secondary and Ancillary Publications ............................. 111 
17.8.2.  Criteria for Determining Authorship ............................................................................ 111 
17.8.3.  Transparency  ................................................................................................................. 112 
17.9.  Suspension or Early Termination  ......................................................................... 112 
17.9.1.  Planned Study Closure  .................................................................................................. 112 
17.9.2.  Early Termination or Suspension  ................................................................................ 112 
17.9.3.  Study-wide termination or suspension  ....................................................................... 112 
17.9.4.  Site termination or suspension  .................................................................................... 113 
17.9
.5. Procedures for Termination or Suspension  ............................................................... 113 
[IP_ADDRESS].  Medtronic -initiated and regulatory authority -initiated  ......................................... [ADDRESS_657504]  Page 10 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  Investigator -initiated  ................................................................................................. 113 
[IP_ADDRESS].  IRB/EC-initiated .......................................................................................................... 114 
18. References  ............................................................................................................... 115 
19. Appendic es .............................................................................................................. 117 
 
Listing of Tables  
Table 1: Study sponsor and monitoring contact [CONTACT_3031] ................................................................. 12 
Table 2: CRO information  ..................................................................................................................  13 
Table 3: Steering Committee contact [CONTACT_3031]  ................................................................................  13 
Table 4: Device Information ..............................................................................................................  33 
Table 5: Visit Schedule and Data Collection Requirements Summary  ....................................................  46 
Table 6: Follow -up Visit Windows  .......................................................................................................  57 
Table 7: Adverse Event and Device Deficiency Reporting Requirements ................................................  73 
Table 8: Adverse Event  Classification Responsibilities  ..........................................................................  77 
Table 9: Investigator reports applicable for all geographies per Medtronic Requirements .....................  103 
Table 10: Additional Investigator reports applicable to the [LOCATION_002] ............................................  104 
Table 11: Investigator reports applicable to Europe ...........................................................................  105 
Table 12: Sponsor Reports for the [LOCATION_002]  ...............................................................................  107 
Table 13: Sponsor reports for Europe  ...............................................................................................  109 
Table 14: Foreseeable Adverse Events  .............................................................................................  123 
Table 15: Arctic Front and Arctic Front Advanceâ„¢ Complications Reported in Literate for Paroxysmal and 
Persistent AF Patients  ...................................................................................................................... [ADDRESS_657505]  Page 11 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Listing of Figures  
Figure 1:  Study Design  .....................................................................................................................  30 
Figure 2: Arctic Front AdvanceTM Cardiac Cryoablation Catheter  ........................................................... 35 
Figure 3: FlexCath AdvanceTM Steerable Sheath with Cryoablation Catheter  ..........................................  36 
Figure 4: Achieveâ„¢ M appi[INVESTIGATOR_54370]  ................................................................................................ 37 
Figure 5: CryoCath CryoAblation Console  ............................................................................................  37 
Figure 6: Coaxial Umbilical Cable  .......................................................................................................  38 
Figure 7: Electrical Umbilical Cable  .....................................................................................................  38 
Figure 8: Manual Retraction Kit  ..........................................................................................................  39 
 
Listing of Appendices  
Appendix A: CRYOBALLOON SAFETY DATA LITERATURE SEARCH ...................................................... 117 
Appendix B: DRAFT DATA COLLECTION ELEMENTS (CASE REPORT FORMS)  ......................................  119 
Appendix C: INFORMED CONSENT FORM TEMPLATE  ........................................................................ 120 
Appendix D: PARTICIPATING INVESTIGATOR AND INSTITUTIONS  ....................................................  121 
Appendix E: IRB LIST  ...................................................................................................................... 122 
Appendix F: FORESEEABLE ADVERSE EVENTS  .................................................................................. 123 
Appendix G: PRE -CLINICAL TESTING  ...............................................................................................  [ADDRESS_657506]  
Clinical Study Type  Pi[INVESTIGATOR_22735] (US)/ Post- market interventional (Europe)  
Product Name  [CONTACT_508806], Inc.  
[ADDRESS_657507] NE  
Mounds View, MN U .S.A. [ZIP_CODE] 
Local Sponsor  Europe  
Medtronic, Bakken Research Center B.V.  
Endeplosdomein 5  
6229 GW Maastricht  
The Netherlands  
Indication Under 
Investigation   Current indication  in the US :  The Arctic  Front Advance â„¢ Cardiac 
CryoAblation Catheter is indicated for the treatment of drug refractory  
recurrent symptomatic paroxysmal atrial fibrillation.  
Indication under investigation for the US :  The Arctic  Front Advance â„¢ 
Cardiac CryoAblation Catheter is indicated for the treatment of recurrent 
symptomatic paroxysmal atrial fibrillation.  
The indication under investigation is within the approved indication in 
Europe. 
Investigation Purpose  The purpose of the s tudy is to  provide data  demonstrating the safety 
and effectiveness of the Arctic Front Advance â„¢ Cardiac CryoAblation 
Catheter  for the treatment of recurrent symptomatic paroxysmal AF, 
without the requirement that the subjects be drug refractory.  
Product Status  The Arctic Front Advance â„¢ Cardiac CryoAblation Catheter is market 
released and will become investigational when used as indicated in the 
study in the US.   The catheter is market released and will be used within 
the approved indication s in Europe, therefore is not consider ed 
investigational for the intended patient population in Europe.   
Primary Objective  Primary Efficacy Objective : 
Demonstrate the superiority of cryoballoon ablation as compared to 
antiarrhythmic drug (AAD)  therapy in terms of the rate of freedom from 
AF/AT/AFL in a non -drug refractory paroxysmal AF population.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657508]  Page 18 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Primary Safety Objective : 
Demonstrate an acceptable safety profile of the cryoballoon ablation 
procedure as a first line therapy in a  non-drug refrac tory paroxysmal AF  
population . 
Secondary Objectives Secondary Objectives are as follows:  
1. Assess changes in quality of life  (QoL) between baseline and 12 
months in the cryoballoon ablation arm.     
2. Compare health care utilization  (HCU) between the treatment 
and control arms.   
   
  
  
  
  
 
  
  
Primary Endpoint  Primary Efficacy Endpoint:  
The primary endpoint is treatment success at 12 months after AAD 
initiation (control arm) or after the pulmonary vein isolation ablation 
procedure utilizing the Arctic Front Advanceâ„¢ Cardiac CryoAblation Catheter  (treatment arm).  A treatment success is the oppo site of a 
treatment failure.  
Treatment failure is defined as any of the following components:  
a) Acute procedural failure (treatment arm only)  
b) Documented AF/AT/AFL on ambulatory monitoring/[ADDRESS_657509] -ablation blanking period (treatment 
arm)/AAD optimization period (control arm)  
o Minimum of 30 seconds on ambulatory monitoring or 10 
seconds on 12 -lead ECG.  
o Note: Documented occurrence and treatment of typi[INVESTIGATOR_508744]-sided cavotricuspid isthmus dependent atrial flutter 
is not considered a failure if confirmed by [CONTACT_508770].  
c) Any subsequent AF surgery or ablation in the left atrium.   
d) Any subsequent cardioversion after the [ADDRESS_657510] -ablation 
blanking period (treatment arm) /AAD optimization period 
(control arm) . 
 

056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657511]  Page 19 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 e) Class I or III antiarrhythmic drug (or sotalol) use after the 90  
day blanking period (treatment arm only).  
The AAD optimization period is defined as the first 90 days after AAD 
initiation (control arm).  The post -ablation blanking period is defined as 
the first 90  days after the index ablation procedure  (treatment arm) .  
Recurrences of atrial arrhythmias during the AAD optimization/blanking 
periods will not be counted in the determination of the first clinical 
failure for th e primary endpoint.   
Within the AAD optimization period/ post-ablation blanking period, 
recurrent arrhythmias can be managed with medications or 
cardioversions.  Reablation will be considered a primary endpoint failure  
at all times, including during the [ADDRESS_657512] -ablation blanking period . 
Acute procedural failure  (treatment arm only) is defined as:  
a) Inability to isolate all accessible targeted pulmonary veins 
(assessed for entrance block and, where assessable, exit block) 
during the index ablation procedur e. 
b) Left atrial non -PVI ablations including but not limited to, ablation 
of linear lesions  
c) Use of a non -study device in the left atrium.  
 
Primary Safety Endpoint:  
The following adverse events will be counted towards the primary safety 
endpoint:  
â€¢ Transient Ischemic Attack  (TIA)within 7 days  
â€¢ Cerebrovascular accident within 7 days  
â€¢ Major bleeding that requires transfusion or results in a 20% or 
greater fall in hematocrit (HCT) within 7 days  
â€¢ Development of a significant pericardial effusion within 30 days.   
A significant pericardial effusion is one that results in 
hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1 -cm or more pericardial 
effusion as documented by [CONTACT_51541].  
â€¢ Symptomatic PV stenosis within 12 months; a ccompanied by 
[CONTACT_080]:  50%-75% reduction in diameter of the 
pulmonary vein, with symptoms not explained by [CONTACT_145037]; OR  >75% reduction in diameter of the pulmonary 
vein  
â€¢ MI within 7 days  
â€¢ PNI unresolved at 12 months  
â€¢ AE fistula within 12  months 
â€¢ Major vascular complication that requires intervention, prolongs 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657513]  Page 20 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 the hospi[INVESTIGATOR_4408], or requires hospi[INVESTIGATOR_063] (within 7 days).   
Secondary Endpoints  1. The difference in composite scores from the AFEQT 
questionnaire taken at baseline and 12 month visits, and the 
difference in composite scores for the EQ- 5D questionnaire 
taken at baseline and 12 -month visits.  
2. 12-month rates of cardiovascular HCU events, and 12 -month 
rates of cardioversion (either electrical or pharmacological) .  
   
  
  
  
  
  
   
  
  
  
  
  
  
  
  
  
  
  
   
  
    
  
 
Study Design  Prospective, interventional, multi -center, randomized, controlled , 
unblinded  clinical study . 
The study will be conducted at up to [ADDRESS_657514]-index cryoballoon ablation procedure 
(treatment arm), or AAD initiation (control arm).  
Subjects will be exited from the study at the conclusion of the [ADDRESS_657515]  Page 21 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Sample Size  210 enrolled subjects in the US and Europe . 
Inclusion/Exclusion 
Criteria The following is a list of inclusion/exclusion  criteria: 
Inclusion criteria  
â€¢ A diagnosis of symptomatic paroxysmal AF with the following 
documentation: (1) physicianâ€™s note indicating recurrent self - 
terminating AF or paroxysmal AF; and (2) any ECG documented 
AF within 6 months prior to enrollment.  
â€¢ Age 18-80 
Exclusion criteria  
â€¢ History of AF treatment with class I or III antiarrhythmic  drug, 
including sotalol,  with the intention to prevent an AF recurrence.  
However, p atients pretreated with above AAD for less than 7 
days with the intention to convert an AF epi[INVESTIGATOR_508745].  
â€¢ Prior persistent AF (cardioversion after 48 hr or continuous AF 
that is sustained  >7 days)  
â€¢ Left atrial diameter greater than 5.0 cm  
â€¢ Prior left atrial ablation or  left atrial  surgical procedure  
â€¢ Presence or likely implant of a permanent pacemaker, biventricu lar pacemaker, loop recorder, or any type of 
implantable cardiac defibrillator (with or without biventricular 
pacing function)  
â€¢ Body mass index (BMI) >40 kg/m
2 
â€¢ Presence of any pulmonary vein stents  
â€¢ Known p resence of any pre -existing pulmonary vein stenosis  
â€¢ Pre-existing hemidiaphragmatic paralysis  
â€¢ Presence of any cardiac valve prosthesis  
â€¢ Moderate or severe mitral valve regurgitation or stenosis  
â€¢ Any cardiac surgery, myocardial infarction, PCI / PTCA or 
coronary artery stenting which occurred during the [ADDRESS_657516] signed the Informed Consent Form  
â€¢ Unstable angina  
â€¢ NYHA class  III or IV congestive heart failure and/or known left 
ventricular  ejection fraction (LVEF) less than 45%  
â€¢ Diagnosis of primary pulmonary hypertension  
â€¢ Rheumatic heart disease  
â€¢ Thrombocytosis, thrombocytopenia  
â€¢ Contraindication to  anticoagulation  therapy 
â€¢ Active systemic infection  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657517]  Page 22 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢ Hypertrophic cardiomyopathy  
â€¢ Cryoglobulinemia  
â€¢ Known reversible causes of AF, including but not limited to 
uncontrolled hyperthyroidism , severe obstructive sleep apnea, 
and acute alcohol toxicity.  
â€¢ Any cerebral ischemic event (strokes or TIAs) which occurred during the [ADDRESS_657518] 
signed the Informed Consent Form , or any known unresolved 
complications from previous stroke/TIA  
â€¢ Existing thrombus  
â€¢ Pregnancy  
â€¢ Patient with life expect ancy that makes it unlikely 12 months of 
follow-up will be completed.   
â€¢ Current or anticipated participation in any other clinical trial of a drug, device or biologic  during the duration of this study not 
pre-approved by [CONTACT_13735]  
â€¢ Patients with contraindications to a Holter monitor  
â€¢ Unwilling or unable to comply fully with study procedures and 
follow-up
 
Study Procedures and Assessments  Subjects in the treatment arm will undergo a pulmonary vein isolation 
(PVI) ablation procedure with the Arctic Front Advance â„¢ Cardiac 
CryoAblation Catheter.   
Subjects in the control arm will be treated with an antiarrhythmic drug as prescribed by [CONTACT_1704].   
Subjects wil l have follow -up visits at 1, 3, 6, and [ADDRESS_657519] -AAD 
initiation or ablation.   Subjects will be exited at the conclusion of the 12 
month visit.   
Safety Assessments  Adverse event data collection will begin once subjects sign the Informed 
Consent Form and will continue through study exit.  For the purposes of 
the study, the following Adverse Events will be collected:  
â€¢ All procedure related AEs  
â€¢ All cryoablation system related AEs  
â€¢ All AAD related AEs  
â€¢ All cardiovascular related AEs 
â€¢ All Serious Adverse Events (SAEs), regardless of relatedness  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657520]  Page 23 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 4. Introduction   
4.1. Background  
Atrial Fibrillation (AF) is a common and disabling cardiac arrhythmia with a heterogeneous clinical 
presentation.  The fundamental pathophysiology consists of atrial wavelets propagating in different 
directions, causing disorganized atrial depolarization without effective atrial contraction, with concomitant 
rapid and irregular ventricular contract ions.  AF can be clinical ly stratified based on  whether epi[INVESTIGATOR_508746]-terminating (paroxysmal) or persistent.  Paroxysmal AF (PAF) is defined as recurrent AF (â‰¥ 2 
epi[INVESTIGATOR_1841]) that terminates spontaneously within 7 days.  Persistent AF is defined as continuous AF that is sustained for greater than 7 days (Calkins, et. al. 2012) . 
AF is the most common of the sustained arrhythmias affecting millions of people worldwide. In the US, AF affects between 2.7 million and 6.1 million adults (January, et al. 2014) , and that number is expected 
to double over the next 25 years (Go, et al. 2001) .  Prolonged AF may lead to electrical, mechanical, and 
structural changes to the left atrium, which may then progress to tachycardia -induced cardi omyopathy, 
heart failure and persistent AF.  The prognosis is related to the underlying cause of the disease, with 
idiopathic causes having the best prognosis and ischemic cardiomyopathy having a poor prognosis.  The 
mortality rate in patients with AF is twice that of patients without AF and the risk of AF- related stroke is 
5-fold compared to the risk in pa tients without AF  (Wolf, Abbott and Kannel 1991) . 
In the US, approved treatment o ptions for newly diagnosed symptomatic paroxysmal AF are limited to 
pharmaceutical therapy because the labeling of cardiac ablation catheters is for â€œdrug refractoryâ€ 
patients.  Patients must be refractory or intolerant to at least 1 class I or III antiarr hythmic drug (AAD) 
before ablation may be attempted.  Pharmacological therapy for AF (paroxysmal and persistent) has 
limited antiarrhythmic efficacy, with recurrence of AF reported at 44% to 67% within one year, based on a systematic review of 45 randomi zed controlled clinical trials (Lafuente -Lafuente, et al. 2006) .  
Treatment with AADs may also result in an increased risk for adverse events. Results of an AFFIRM sub 
study showed that adverse events resulting in discontinuation of the treatment were common for AADs, 
occurring in 11.1% to 28.1% of patients, depending on the AAD used  (AFFIRM First Antiarrhythmic Drug 
Substudy Investi. 2003) .  The RAAFT -2 study found that AADâ€™s had a success rate of 42% at one year in 
61 previously treatment -naive paroxysmal AF patients; meanwhile, the 2014 AHA/ACC/HRS guideline for 
the management of patients with AF stated that â€œmuch like other antiarrhythmic drugs, with the 
exception of amiodarone, the rates of maintain ing sinus rhythm at 1 year for sotalol are 30 -50%â€ 
(January et. al.  2014) (Morillo, et al. 2014) . 
Atrial fibrillation is known to cause electrical remodeling of the atria as well as structural changes that 
promote perpetuation  and progressi on of symptoms (Wijesurendra and Casadei 2015) (Shulka and Curtis 
2014) (Jalife and Kaur 2015) .  Untreated PAF  can give rise to persistent or permanent for ms of the 
disease (De Vos, et al. 2010) , which may be more resistant to contemporary AF treatments (Oral, et al. 
2002) (Romero, et al. 2015) .  As such, early and effective intervention is key for normalizing sinus rhythm 
(SR) and preventing further remodeling and disease progression (Nattel, et al. 2014)  (Cosio, et al. 2008) .  
AAD treatmen ts have little to no effect on remodeling (Nattel, et al. 2014)  and although may restore SR 
in the short -term, have high long -term rela pse rates (45 -90%) (Cosio, et al. 2008)  making this treatment 
largely ineffective at preventing progression of AF.  By [CONTACT_22242], early evidence seems to indicate that 
catheter ablation may reverse indicators of structural remodeling associated w ith AF (Walters, et al. 
2016) (Wu, et al. 2016) .  Furthermore, catheter ablation, particularly using the  Arctic Front Advance â„¢ 
Cardiac CryoAblation Catheter, hereafter also referred to as the cryoballoon, has a much higher efficacy 
rate and may be even more effective when  provided earlier after AF onset (Arena, et al. 2016)  (Tanner, 
et al. 2011) . 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657521] evolved over time and currently include pulmonary 
vein isolation (PVI)  as a cornerstone of ablation therapy in all types of AF (paroxysmal and persistent)  
(Raviele 2012)  (Jais, et al. 2006) .  AF arises primarily from the left side of the heart in (or near) the 
atrium, particularly where the pulmonary veins (PVs)  join the atrium.  The fundamental basis for the AF 
ablation procedure is the creation of myocardial lesions that block the propagation of AF wave fronts from 
the triggering source.  The muscular sleeves within the PVs have been established as a  critical source of 
AF triggers (Caulkins and et. al. 2007) . 
The safety profile of cryoballoon ablation is also well established. The STOP AF trial (Packer, et al. 2013)  
was a prospective,  multicenter, randomized, controlled investigation device exempti on (IDE) study 
designed to compare outcomes of cryoballoon and antiarrhythmic drug therapi[INVESTIGATOR_54362].  
Six point one percent  (6.1%) of cryoballoon subjects experienced a procedure- related event or major 
adverse event versus 8.5% of AAD subjects.   An analysis of 149 cryoballoon studies with 11,242 patients 
(see Appendix A for literature search methodology) showed similar complication r ates to STOP AF.  
The STOP AF Post Approval Study was designed to provide long -term safety and effectiveness of the 
Arctic Front and Arctic Front Advanceâ„¢ Cardiac Cryoablation Catheter System, including the FreezorÂ® 
MAX Cardiac cryoablation catheter acc ording to the Product Labeling.   Inexperienced users were selected 
as study Investigators in order to understand complication  rates in a real world setting.  There were [ADDRESS_657522]- ablation procedure.  Major procedure related events occurred in 20/341 
patients (5.9% of pa tients and 5.7% of procedures).  No device or procedure related deaths were 
reported (Knight, e t al. 2016) . 
4.2. Purpose  
The purpose of the STOP AF First study is to provide data demonstrating the safety and effectiveness of 
the Arctic Front AdvanceTM Cardiac CryoAblation Catheter  for the treatment of recurrent symptomatic 
paroxysmal AF , without the  requirement that subjects be drug refractory .  The current indication is the 
US is as follows: The Arctic  Front Advance â„¢ Cardiac CryoAblation Catheter is indicated for the treatment 
of drug refractory  recurrent symptomatic paroxysmal atrial fibrillation.  The proposed indication  in the US 
is as follows: The Arctic Front Advance â„¢ Cardiac CryoAblation Catheter is indicated for the treatment of 
recurrent symptomatic paroxysmal atrial fibrillation. The proposed indication is within the approved 
indication s for use in Europe.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657523]  Page 25 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 5. Objective s and Endpoints  
5.1. Objectives  
 Primary Objective (s) 5.1.1.
[IP_ADDRESS].  Primary Efficacy Objective  
Demonstrate the superiority of cryoballoon ablation as compared to AAD therapy in terms of the rate of 
freedom from AF/AT/AFL in a non -drug refractory paroxysmal AF population.  
[IP_ADDRESS].  Primary Safety Objective  
Demonstrate an acceptable safety profile of the cryoballoon ablation procedure as a first line therapy in a 
non-drug refractory paroxysmal AF population . 
 Secondary Objective s 5.1.2.
Secondary Objectives are as follows : 
1. Assess changes in quality of life  between baseline and [ADDRESS_657524]  Page 26 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Primary Endpoint  5.1.4.
[IP_ADDRESS].  Primary Efficacy Endpoint 
The primary endpoint is treatment success at 12 months after AAD initiation (control arm) or after the 
pulmonary vein isolation ablation procedure  utilizing the Arctic Front Advance â„¢ Cardiac CryoAblation 
Catheter  (treatment arm) .  A treatment success is the opposite of a treatment failure.  
Treatment failure is defined as a ny of the following components:  
a) Acute procedural failure  (treatment arm only)  
b) Documented AF/AT/AFL on ambulatory monitoring/ 12-lead ECG a fter the [ADDRESS_657525]-ablation 
blanking period  (treatment arm)/AAD optimization period (control arm).   
o Minimum of 30 seconds on ambulatory monitoring  or 10 seconds on 12-lead ECG . 
o Note: Documented occurrence and treatment of typi[INVESTIGATOR_169244] -sided cavotricuspid isthmus 
dependent atrial flutter is not considered a failure if confirmed by [CONTACT_508770].  
c) Any subsequent  AF surgery or  ablation in the left atrium.  
d) Any subsequent cardioversion after the [ADDRESS_657526] -ablation blanking period (treatment 
arm)/AAD optimization period (control arm) . 
e) Class I or III antiarrhythmic drug (or sotalol ) use after the 90 day blanking period  (treatment arm 
only). 
The AAD optimization period is defined as the first 90 days after AAD initiation (control arm).  The post-
ablation b lanking period is defined as the first 90  days after the index ablation procedure  (treatment 
arm).  Recurrences of atrial arrhythmias during the AAD optimization/ blanking pe riods will not be counted 
in the determination of the first clinical failure for the primary endpoint.   
Within the AAD optimization period/ post-ablation blanking period, recurrent arrhythmias can be manage d 
with medications or cardioversions.  Reablation  will be considered a primary endpoint failure  at all times, 
including during the [ADDRESS_657527] -ablation blanking period . 
Acute procedural failure  (treatment arm only) is defined as:  
a) Inability to isolate all accessible targeted pulmonary veins (assessed for entrance block and, 
where assessable, exit block) during the index ablation procedure.  
b) Left atrial non -PVI ablations including but not limited to, ablation of linear lesions  
c) Use of a non -study device in the left atrium.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657528]  Page 27 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  Primary Safety Endpoint  
The follo wing adverse events will be counted towards the primary safety endpoint:  
â€¢ TIA within 7 days  
â€¢ Cerebrovascular accident within 7 days  
â€¢ Major bleeding that requires transfusion or results in a 20% or greater fall in hematocrit (HCT) 
within 7 days  
â€¢ Development of a significant pericardial effusion within 30 days.   A significant pericardial 
effusion is one that results in hemodynamic compromise, requires elective or urgent 
pericardiocentesis, or results in a 1 -cm or more pericardial effusion as documented by 
[CONTACT_51541].  
â€¢ Symptomatic PV stenosis within 12 months; accompanied by  [CONTACT_080] : 50%-75% 
reduction in diameter of the pulmonary vein , with symptoms not explained by [CONTACT_145037]; 
OR >75% reduction in diameter of the pulmonary v ein  
â€¢ MI within 7 days  
â€¢ PNI unresolved at 12 months  
â€¢ Atrial-esophageal  fistula within 12 months  
â€¢ Major vascular complication that requires intervention, prolongs the hospi[INVESTIGATOR_4408], or requires 
hospi[INVESTIGATOR_063] (within 7 days).   
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657529]  Page 28 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Secondary Endpoint s 5.1.5.
1. The difference in composite scores from the AFEQT questionnaire taken at baseline and 12 
month visits, and the difference in composite scores for the EQ -5D questionnaire taken at 
baseline and 12 -month visits.  
â€¢ The AFEQT and EQ-5D questionnaires will be utilized f or this objective.  The AFEQT 
questionnaire is an atrial fibrillation specific health -related quality of life questionnaire to 
assess the impact of AF on a subjectâ€™s life.  The overall score ranges from 0 â€“100, where [ADDRESS_657530] appropriate sta tement.  The second section is a visual analog scale . 
2. 12-month rates of cardiovascular  health care utilization ( HCU) events, and 12- month rates of 
cardioversion (either electrical or pharmacological).  
â€¢ The number of cardiovascular -related hospi[INVESTIGATOR_602], emergency department visits, and 
unscheduled visits will be reported and compared between the treatment and control arms.   
â€¢ The number of electrical and pharmacological cardioversions experienced by [CONTACT_508771].    
  
   
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  

056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657531]  Page 29 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢  
 
 
 
 
  
  
 
  
 
  
 
 
   
  
 
  
 
  
  
 
 
  
  

)&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI


9HUVLRQ 6723$))LUVW 3DJH RI
$35 &OLQLFDO,QYHVWLJDWLRQDO3ODQ
 0HGWURQLF&RQILGHQWLDO 6WXG\'HVLJQ
0HGWURQLF,QFLVVSRQVRULQJWKH6 723$))LUVWVWXG\DSURVSH FWLYHLQWHUYHQWLRQD OPXOWLFHQWHU
UDQGRPL]HGFRQWUROOHGXQEOLQG HGFOLQLFDOVWXG\7KHVWXG\ZL OOEHFRQGXFWHGDWXSWRVLWHVLQWKH86
DQGXSWRLQ(XURSH7ZRKXQG UHGDQGWHQVXEMHFWVZLO OEHHQUROOHG7KHPD[LPXPQXPEHURI
VXEMHFWVWKDWPD\EHUDQGRPL]H GDWDVLQJOHFHQWHUZLOOEHV XEMHFWVRIWKHWRWDOVXEMHFWV
UDQGRPL]HG1RJUHDWHUWKDQ RIWKHVXEMHFWVZLOOEHHQURO OHGRXWVLGHRIWKH867KHUHLVQR
PLQLPXPQXPEHURIUHTXLUHGHQUROOPHQWVSHUVLWHKRZHYHUVLWHV ZLOOEHHQFRXUDJHGWRHQUROODQG
UDQGRPL]HDWOHDVWVXEMHFWV 6XEMHFWVZLOOEHUDQGRPL]HGWR HLWKHU$$'WKHUDS\FRQWURODUPRU
FU\RDEODWLRQWUHDWPHQWDUP 6XEMHFWVZLOOEHIROORZHGDWP RQWKPRQWKVPRQWKVDQGPRQWKV
IROORZLQJHLWKHUFU\RDEODWLRQRU$$'LQLWLDWLRQ6XEMHFWVZLOO EHH[LWHGIURPWKHVWXG\DWWKHPRQWK
IROORZXSYLVLW$WOHDVWRQH$U FWLF)URQW$GYDQFH&U\R$EODWLR Q&DWKHWHUZLOOEHXVHGSHUVXEMHFWLQWKH
WUHDWPHQWDUP$GGLWLRQDOFDWKHWHUVPD\EHXVHGLQWKHFDVHRI UHDEODWLRQRUFURVVRYHUDEODWLRQDWOHDVW
RQHSHUVXEMHFW

)LJXUH6WXG\'HVLJQ


056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657532]-index 
cryoballoon ablation procedure  (treatment arm), or AAD initiation (control arm) . 
Subjects will be exite d from the study at the conclusion of the [ADDRESS_657533] follow -up.  Subjects will not be replaced with newly enrolled subjects upon early study exit. The 
objectives will be analyzed for a Premarket Approval Supplement (PMA -S) after all randomized subjects 
complete 12 months of follow -up after the index cryoballoon ablation procedure (treatment arm), or AAD 
initiation (con trol arm).  
6.2. Rationale  
The study has primary objective s designed to evaluate the safety and effectiveness of the Arctic Front 
Advanceâ„¢ Cardiac CryoAblation Catheter for treatment of recurrent symptomatic p aroxysmal AF.  In the 
US, there are no ablation cathe ters approved to treat patients with paroxysmal AF unless they have 
demonstrated intolerance or refractoriness to anti -arrhythmic drug therapy.  The study will provide 
patients with more options for treatment and the possibility of improving their health  and quality of life 
and a decrease  in stroke risk .  If successful, the STOP AF  First study will demonstrate meaningful 
therapeu tic benefit in this population.  This evaluation will support an indication expansion for the 
treatment of recurrent symptomatic paroxysmal AF.  The study will be considered successful if it meets 
the primary objective s, contingent upon FDA review and approval.  
The study will compare cryoablation to AAD therapy, the current standard of care for subjects 
experiencing atrial fibrillation for the first time.   
Cryoablation efficacy will be demonstrated by [CONTACT_508772] a higher rate of efficacy success than the AAD arm (treatment success described in Section 
[IP_ADDRESS]).  The STOP AF Pi[INVESTIGATOR_508747] 69.9%.  Several trials were 
completed comparing radiofrequency ablation to AADs in the same non -drug refractory patient population 
(Nielsen, et al. 2012)  (Morillo, et al. 2014)  (Wazni, et al. 2005) .  The RAAFT -2 study monitored for 
recurrent arrhythmia in a manner similar to the requirements of this protocol; they required regular and 
symptomatic transtelephonic monitor transmissions (Morillo, et al. 2014).  In RAAFT -2, approximately 
45% of subjects in the AAD arm experienced recurrent atrial fi brillation by [CONTACT_122467].  The superiority 
analysis in this study is designed to show that subjects in the cryoablation treatment arm will experience 
less AF recurrence than subjects in the AAD arm, assuming similar recurrence rates to those in the STOP 
AF Pi[INVESTIGATOR_508748] -2.   
Cryoablation safety will be demonstrated by [CONTACT_508773] a pre-specified list of known 
potential complications is consistent with previous trials and cur rent literature  (Packer, et al. 2013) . 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657534]  Page 32 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 6.3. Minimization of Bias  
Selection of subjects, treatment of subjects, and evaluation of study data are potential sources of bias.  
Methods incorporated in the study design to minimize potential bias include (but are not limited to):  
â€¢ Subjects will undergo screening to confirm eligibility for enrollment with defined 
inclusion/exclusion criteria prior to enrollment.  
â€¢ Subject demographics will be collected at baseline in order to later assess possible characteristics that may influence endpoints.  
â€¢ All centers and geographies will use the same version of the clinical investigation plan and case 
report forms.  
â€¢ All investigational center personnel and Medtronic personnel will be trained on their respective aspects of the study using standardized training materials. 
â€¢ All investigational center personnel will be trained on and required to follow the CIP.  
â€¢ An independent Clinical E vents Committee (CEC) will be utilized regularly to  review and 
adjudicate reported adverse events  and deaths .   
â€¢ An independent core lab will be utilized to review and adjudicate all ECG recordings  from study 
required 12 -lead ECGs and ambulatory monitoring . 
â€¢ A statistical analysis plan  (SAP) will be developed prior to analyzing data.  The plan will document 
all pre-specified analyses and analysis methods.  
â€¢ Monitoring will be conducted to review adherence to the CIP and perform source data verification per the Monitoring Plan.  
â€¢ A maximum of 31 treated subjects will be allowed at a single investigational center to ensure an even distribution of total subjects across centers.  
â€¢ All study investigators in all geographies will be required to comply with 21CFR Part 54, Financial 
Disclosure by [CONTACT_6230].  
In summary, potential sources of bias that may be encountered in this clinical study  have been 
considered and minimized by [CONTACT_169257] , careful study design.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657535]  Page 35 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 7.2. Arctic Front Advance â„¢ Cardiac CryoAblation Catheters  
In the US, the Arctic Front Advance â„¢ Cardiac CryoAblation Catheters  (23mm and 28mm)  are FDA 
approved  and indicated for the treatment of drug refractory recurrent symptomatic p aroxysmal atrial 
fibrillation. 
The investigational indication in the US is for the treatment of recurrent symptomatic paroxysmal atrial 
fibrillation without the requirement  that the A F be drug refractory . 
In Europe, the Arctic Front AdvanceTM Cardiac CryoAblation Catheters (23mm and 28mm) are  CE marked 
and indicated for the treatment of patients with atrial fibrillation.  The catheter is not considered 
investigational for the intended patie nt population in Europe , as it is being used within the approved 
indication. 
The catheters are sterile, single use, minimally invasive intravascular balloon catheters specifically 
designed for tissue cryoablation.  The Arctic Front Advanceâ„¢ Cardiac CryoAbl ation Catheter is used 
together with the CryoConsole and related devices.   Arctic Front Advance â„¢ Cardiac CryoAblation  
Catheters are percutaneously advanced to the heart chamber from the femoral access via a transseptal 
sheath in the vasculature.  Once the catheter reaches the left atrium, the balloon is inflated and the 
cooling segment creates circumferential lesions at the antrum of the targeted pulmonary veins.  
Figure 2 : Arctic Front AdvanceTM Cardiac Cryoablation  Catheter  
 
7.3. Freezor Â® MAX Cardiac Cr yoAblation Catheters  
In the US and Europe, the FreezorÂ® MAX Cardiac CryoAblation Catheter is market released and approved 
for use in the study intended patient population, therefore, is not considered investigational.   
Approved ind ication in the US: The FreezorÂ® MAX Cardiac CryoAblation Catheter is used as an adjunctive 
device in the endocardial treatment of paroxysmal atrial fibrillation in conjunction with the Arctic Front 
Advanceâ„¢ Cardiac CryoAblation Catheter.  

056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657536]  Page 36 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 
Approved indicatio n in Europe: The FreezorÂ® MAX Cardiac CryoAblation Catheter is intended for use in 
the treatment of cardiac arrhythmias.  
The Freezor Â® MAX Cardiac CryoAblation  Catheter is a flexible, steerable catheter used to ablate cardiac 
tissue.  It is used together with the CryoConsole and related components.  The tip of the Freezor Â® MAX 
Cryocatheter reaches cryoablation temperatures when refrigerant is injected from the C ryoConsole to the 
tip of the catheter.  The catheter tip has an integrated thermocouple for temperature reading capability.  
The catheter is introduced into the vasculature by [CONTACT_54411].  
7.4. FlexCath Advanceâ„¢ Steerable Sheath  
The FlexCath AdvanceTM Steerable Sheath is a percutaneous introducer fitted with a hemostasis valve to 
allow for introduction, withdrawal and swappi[INVESTIGATOR_54363] a barrier 
preventing air ingress into the valve and minimizing blood  loss.  A side -port with stopcock is integrated 
into the hemostasis valve to allow continuous drip infusion, injection through the center lumen, flushing, aspi[INVESTIGATOR_1516], blood sampling and pressure monitoring.  The FlexCath Advance
TM Steerable Sheath is 
intended to allow sheath deflection to facilitate catheter positioning.  It is supplied sterile and packaged 
together with a dilator.  
 
Figure 3: FlexCath AdvanceTM Steerable Sheath with Cryoablation Catheter  
 
7.5. Achieveâ„¢ or Achieve Advance â„¢ Mappi[INVESTIGATOR_508749]-cardiac electrophysiology diagnostic 
catheters indicated for multiple electrode electrophysiological mappi[INVESTIGATOR_508750], i.e., recording o r stimulation only.  The AchieveTM and Achieve Advance Mappi[INVESTIGATOR_54370] s are 
designed to obtain electrograms in the atrial regions of th e heart. 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657537]  Page 37 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Figure 4: Achieve â„¢ Mappi[INVESTIGATOR_54370]  
 
7.6. CryoCath CryoAblation Console  
The CryoConsole houses the electronics and compatible software for controlling and recording the 
ablation procedure, stores and controls delivery of liquid refrigerant under high pressure through the co -
axial umbilical to the catheter, recovers the expanded refrigerant v apor from the catheter under vacuum, 
and disposes of the refrigerant through the hospi[INVESTIGATOR_54364].  
The hardware controls the safety monitoring system while the software provides the user interface 
patient information, procedure temperature, time set point in automatic mode and procedure data 
information.  
Figure 5: CryoCath CryoAblation Console  
 

056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657538]  Page 38 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 7.7. Coaxial Umbilical Cable 
The Sterile Coaxial Umbilical delivers the Nitrous Oxide (N2O) gas  from the console to the catheter and 
transports refrigerant vapors from the catheter to the console, which is then vented into the hospi[INVESTIGATOR_508751].  
Figure 6 : Coaxial Umbilical Cable  
 
7.8. Electrical Umbilical Cable 
The Sterile Electrical Umbilical is an electrical extension cable that transports:  
â€¢ Temperature feedback f rom the catheter to the console  
â€¢ Leak detection signals f rom the catheter to the console  
â€¢ Blood sensor signals f rom the catheter to the console  
â€¢ Pressure sens or form the catheter to the console  
 
Figure 7 : Electrical Umbilical Cable  
  
 
7.9. Manual Retraction Kit  
The manual retraction kit contains one large syringe, one [ADDRESS_657539] stopcock and a coaxial -to-luer adaptor.  
The kit is used during the  rewrap procedure of the Arctic Front Advance â„¢ Cardiac CryoAblation Catheter 
if the physician cannot retract the catheter using the normal catheter retraction cycle.  

056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657540]  Page 39 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Figure 8 : Manual Retraction Kit  
 
7.10. Additional Study Devices  
Medtronic may incorporate additional components, software, and devices into this clinical study as they 
receive appropriate license or regulatory approval and are released commercially by [CONTACT_508774].  
7.11. Product Training Requirements  
Physicians performing the cryoablation procedure must have been trained in the handling of Arctic Front Advanceâ„¢ Cardiac CryoAblation Catheter and CryoCath Cardiac CryoAblation System .  They must be 
qualified by [CONTACT_508775] ( US ONLY ), and must have p erformed at least 
20 ablation procedures with Arctic Front or Arctic Front Advance â„¢ and associated products . 
7.12. Packaging 
In the US and Europe, the Arctic Front Advanceâ„¢ Cardiac CryoAblation Catheters will not be labeled as 
investigational.  T hese devices will be considered investigational upon opening per the CIP  (US only) . 
Commercially available products will be used for the study.  
7.13. Investigational Device Storage, Handling and Traceability  
The Arctic Front Advance â„¢ Cardiac CryoAblation Catheters used in this study are commercially available  
in the US and Europe ; they will not be labele d as investigational and will not be provided to the 
investigational centers. 
The Arctic Front Advanceâ„¢  Cardiac CryoAblation Catheter will be considered investigational in the US 
when opened with the  intent to use in this study.  The catheter  is market -released and will be used 
within the approved indication in Europe, therefore, will be considered non -investigational in Europe.  
In the US, d evice tracking information will be entered into the study database for any catheter that is 
considered investigational in this study .  The device tracking information must be maintained and 
updated when the investigational catheter is disposed of or returned to Medtronic.  

056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657541]  Page 40 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 NOTE: this is a deviation to Section 18.[ADDRESS_657542] because device accountability for the Arctic 
Front Advanceâ„¢  Cardiac CryoAblation Catheters will not be performed in Europe and only upon package 
opening with the intent of using the catheter for a study subject in the US.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657543]  Page 41 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 8. Investigator/Investigator Center Selection  
All clinical Investigators managing the subjectâ€™s arrhythmia must be qualified practitioners and 
experienced in the diagnosis and treatment of subjects with atrial arrhythmias. Investigators performing the cryoablation procedure must have been trained in the handling of Arctic Front Advan ceâ„¢ Cardiac 
CryoAblation Catheters.  
 
The role of the Principal Investigator [INVESTIGATOR_54365] -to-day conduct of the clinical  
investigation as well as ensure data integrity and the rights, safety and well- being of the subjects 
involved in t he clinical investigation.  
 
The minimum required criteria for a Principal Investigator [INVESTIGATOR_508752]: 
â€¢ Investigator/site is qualified by [CONTACT_45437], education, and relevant experience appropriate to the 
use of the product and associated procedures.   
â€¢ Investigator/site expects to have adequate time and resources to conduct the study throughout the duration of the study.  
â€¢ Investigator/site has access to an adequate number of eligible subjects.  
â€¢ Ability to comply with applicable Institutional Review Board (IRB)/Ethics Committee (EC) and regulatory requirements . 
â€¢ Investigator is not debarred, disqualified, or working under sanctions in applicable regions. 
 
Center personnel training will be completed prior to participation  in this clinical study.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657544]  Page 42 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 9. Center Activation  
During the activation process (prior to subject enrollment), Medtronic will train center personnel on the 
CIP, relevant standards and regulations, informed consent, and on data collection and reporting tools. If  
new members join the study center team, they will receive training on the applicable clinical study 
requirements relevant to their role before contributing to the clinical study.  
 Prior to performing study related activities, all local regulatory requirements shall be fulfilled, including, 
but not limited to the following:  
 
â€¢ IRB/MEC approval (and membership roster/voting list) of the current version of the CIP, Patient Informed Consent Form, subject facing materials, Report of Prior Investigation, Investiga tor 
Brochure as required by [CONTACT_54414], as necessary.  
â€¢ Regulatory authority approval or notification (as required per local law)  
â€¢ Fully executed Clinical Trial Agreement (CTA) and Investigator Statement where applicable  
â€¢ Financial Disclosure of Investigators 
â€¢ Curriculum Vitae (CV) of Investigators and key members of the investigation center team (as  
required by [CONTACT_1769]) (in Europe, CVs are required for the Principal Investigator [INVESTIGATOR_508753])  
â€¢ Documen tation of delegated tasks  
â€¢ Documentation of study training  
 Documentation of delegated tasks must be completed prior to any person other than the Principal  
Investigator [INVESTIGATOR_502945].  
 Additional requirements imposed by [CONTACT_1201]/MEC and regulatory authority shall be followed.  
 In addition, all participating center staff must be trained on the current version of the CIP and must be  
delegated by [CONTACT_079] [INVESTIGATOR_180984].  
 Medtronic will provide each study center with documentation of study center/Investigator readiness in the 
form of a center readiness letter; this letter must be received prior to subject enrollment. Additional center personnel included after the initial activation will be notified when all requirements have been completed.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657545]  Page 43 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 10. Selection  of Subjects  
10.1. Study Population  
The study population includes adult patients with recurrent symptomatic paro xysmal atrial fibrillation.  
The AF classifications that will be used for this study are defined in the 2012 HRS/EHRA/ECAS Expert 
Consensus Statement on Catheter and Sur gical Ablation of Atrial Fibrillation . (Calkins, et. al. 2012)  
Paroxysmal AF is defined as recurrent AF (â‰¥2 epi[INVESTIGATOR_1841]) that terminates spontaneousl y within 7 days.  
Epi[INVESTIGATOR_298261] â‰¤ 48 hoursâ€™ duration that are terminated with electrical or pharmacologic cardioversion 
will be classified as paroxysmal AF epi[INVESTIGATOR_1841].  
Patients in persistent AF  are excluded from the study.  Persistent AF is defined as conti nuous AF that is 
sustained beyond 7 days.  Epi[INVESTIGATOR_137844] a decision is made to electrically or pharmacologically 
cardiovert the patient after â‰¥ [ADDRESS_657546] (IRB) /Ethics Committee ( EC) and Medtronic 
approval of this CIP and the Informed Consent Form (ICF) must be obtained prior to enrolling subjects in 
the study.  Subjects are considered enrolled in the study upon signing and dating the ICF.  Subjects must 
provide informed consent (IC) before any study related procedures occur.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657547]  Page 44 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 10.3. Inclusion C riteria 
â€¢ A diagnosis of symptomatic paroxysmal AF with the following documentation: (1) physicianâ€™s note 
indicating recurrent self - terminating AF  or paroxysmal AF; and (2) any ECG documented AF 
within 6 months prior to enrollment .  
â€¢ Age 18-80 
10.4. Exclusion Criteria 
â€¢ History of AF treatment with class I or III antiarrhythmic  drug, including sotalol,  with the 
intention to prevent an AF recurrence.  However, patients pretreated with above AAD for less 
than 7 days with the intention to convert an AF epi[INVESTIGATOR_130199] a llowed. 
â€¢ Prior persistent AF (cardioversion after 48 h ours or continuous AF that is sustained  >7 days)  
â€¢ Left atrial diameter greater than 5.0 cm  
â€¢ Prior left atrial ablation or left atrial surgical procedure  
â€¢ Presence or likely implant of a permanent pacemaker, biventricular pacemaker, loop recorder, or 
any type of implantable cardiac defibrillator (with or without biventricular pacing function)  
â€¢ Body mass index (BMI) > 40 kg/m2 
â€¢ Presence of any pulmonary vein stents  
â€¢ Known presence of any pre -existing pulmonary vein stenosis  
â€¢ Pre-existing hemidiaphragmatic paralysis  
â€¢ Presence of any cardiac valve prosthesis  
â€¢ Moderate or severe mitral valve regurgitation or stenosis  
â€¢ Any cardiac surgery, myocardial infarction, PCI / PTCA or coronary artery stenting which occurred 
during the [ADDRESS_657548] signed the Informed Consent Form  
â€¢ Unstable angina  
â€¢ NYHA class III or IV congestive heart failure and/or known left ventricular ejection fraction (LVEF) less than 45%  
â€¢ Diagnosis of primary pulmonary hyper tension 
â€¢ Rheumatic heart disease  
â€¢ Thrombocytosis, thrombocytopenia  
â€¢ Contraindication to anticoagulation therapy  
â€¢ Active systemic infection  
â€¢ Hypertrophic cardiomyopathy  
â€¢ Cryoglobulinemia 
â€¢ Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism, severe obstructive sleep apnea, and acute alcohol toxicity.  
â€¢ Any cerebral ischemic event (strokes or TIAs) which occurred during the [ADDRESS_657549] signed the Informed Consent Form, or any known unresolved 
complications from previous stroke/TIA  
â€¢ Existing thrombus  
â€¢ Pregnancy  
â€¢ Patient with life expectancy that makes it unlikely [ADDRESS_657550]  Page 45 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢ Current or anticipated participation in any other clinical trial of a drug, device or biologic during 
the duration of this study not pre -approved by [CONTACT_13735]  
â€¢ Patients with contraindications to a Holter monitor  
â€¢ Unwilling or unable to comply fully with study procedures and follow -up 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657551] IRB /EC approval as well as 
documentation from Medtronic of center readiness. 
11.1. Schedule of Events  
The visit schedule and data collection requirements are summarized in  Table 5. 
Table 5: Visit Schedule and Data Collection Requirements Summary  
 
Baseline 
Procedure  
Hospi[INVESTIGATOR_138007]  
1M 
3M  
6 & 12 M  
Unscheduled  
Reablation/ 
Crossover Ablation  
Treatment 
Arm Only  
Informed Consent  X        
Randomization  X        
Inclusion/Exclusion  X        
Medical History  X        
Physical Exam  X        
Pregnancy Screening1 X        
Review Medications  X  X X X X X X 
Review of AF Symptoms  X   X X X X X 
Collect Health Care Utilization 
Information     X X X X X 
12 Lead ECG  X  X X X X X  
EQ-5D & AFEQT  X     X  X 
Trans-thoracic Echocardiogram 
(TTE)2 X        
Trans-esophageal 
Echocardiogram (TEE)[ADDRESS_657552] be performed in all subjects who present to the ablation procedure in atrial fibrillation lasting more than 48 hours in 
duration (or of an unknown duration).  However, the TEE is not required if the subject has adequate systemic anticoagulation that 
has been maintained for at least [ADDRESS_657553] a CHA2DS2 -VASc â‰¥2 and present to the procedure with a sub -therapeutic INR  (<2.0) or if the subject has had a significant 
interruption of NOACs.  A significant interruption of NOACs is defined as any missed dose within [ADDRESS_657554]  Page 47 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  
Baseline 
Procedure  
Hospi[INVESTIGATOR_138007]  
1M 
3M  
6 & 12 M 
Unscheduled  
Reablation/ 
Crossover Ablation  
Treatment 
Arm Only  
Ablation Procedure Data   X      X 
[ADDRESS_657555] X-ray  
(treatment arm only)  If phrenic nerve injury is detected during the procedure, 
the subject will be evaluated with inspi[INVESTIGATOR_1516]/expi[INVESTIGATOR_508754] x-ray at PHD and all follow -up visits until resolved.  
MRI or CT Scan  
(treatment arm only)  Required only for subjects with suspected PV stenosis.   
11.2. Medications  
Information regarding drugs prescribed to treat atrial arrh ythmias will be collected, including the purpose 
for their use /reason for modification , and start and stop dates.  Information regarding anticoagulation 
mediations will be collected, including start and stop dates.  
Control Arm (AAD):   Subjects must initiate a Class I or III AAD within [ADDRESS_657556] of care; however, 
amiodarone should only be used if other AADs were not  tolerated or failed.  The 2014 AHA/ACC/HRS 
Guideline for the Management of Patients with AF should be consulted for AAD prescriptions .  
Modifications to AADs (type or dosage  increase ) may be made for up to [ADDRESS_657557] allowed only up to physiciansâ€™ discretion to guarantee the safety of the 
patients.   The possible concomitant use of beta blockers  can still be optimized after the optimization  
period. 
                                                
 
4 Subjects shall submit ECG transmissions weekly and whenever symptoms occur  after the AAD optimization/post- ablation blanking 
periods through [ADDRESS_657558]  Page 48 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Treatment Arm (Cryoablation):   Subjects may be prescribed Class I or III AAD s for up to [ADDRESS_657559]-ablation .  Use of amiodarone is not permitted.  
Anticoagulation requirements for all subjects:  
Anticoagulation pre-procedure should be determined based upon the subjects CHA 2DS2-VASc score.   
a. Oral anticoagulants are required if the subject has had a prior stroke or TIA, or if the subject 
has a CHA 2DS2-VASc score  â‰¥2.  When anticoagulation is required, subjects must take it for 
at least 21 days prior to an  ablation procedure.   
b. Oral anticoagulants are not required for subjects with nonvalvular AF and a CHA 2DS2-VASc 
score of 0 or 1.  
Note:  TEE must be performed within one day prior to t he cryoablation  procedure if subjects have a 
CHA2DS2- VASc â‰¥2 and present to the procedure with a sub -therapeutic INR (<2.0) or if the subject has 
had a significant interruption of NOACs.  A significant interruption of NOACs is defined as any missed 
dose within [ADDRESS_657560] Consent  
Patient informed consent (IC) is defined as a legally effective documented confirmation of a subjectâ€™s (or their legally authorized representative, US ONLY ) voluntary agreement to participate in a particular 
clinical study after information has been given to the subject on all aspects of the clinical study that are relevant to the subjectâ€™s decision to participate. This process includes obtaining an Informed Consent 
Form (ICF) and an Authorization to Use and Disclose Personal Health Information that has been approved 
by [CONTACT_5243]â€™s IRB/EC and signed and dated by [CONTACT_423] (or their legally authorized 
representative, US ONLY ). A subject may only consent after information has been given to the subject on  
all aspects of the clinical investigation that are relevant to the subjectâ€™s decision to participate. Informed consent may be given by [CONTACT_508776] ( US ONLY ) only if a subject is unable to 
make the decision to participate in a clinical investigation. In such cases, the subject shall also be informed about the clinical investigation within his/her ability to understand.  
 
Prior to enrolling subjects, the ICF must have been approved by [CONTACT_37330]â€™s IRB/EC. Each site must 
also use a n Authorization to Use and Disclose Personal Health Information/Research Authorization/other 
privacy language as required by [CONTACT_2371]. The ICF must be controlled (i.e. versioned and  dated) to ensure it is 
clear which version(s) were approved by [CONTACT_1201]/EC. Any modifications to the sample ICF must be 
reviewed and approved by [CONTACT_169267]/EC reviewing the application prior to enrolling subjects.  
 The Investigator must notify the subject ( US ONLY: or their legally -authorized representative) of any 
significant new findings about the study that become available during the course of the study which are 
pertinent to the safety and well -being of the subject. This could impact a subjectâ€™s willingness to 
participate in the study. If relevant, approval may be requested from subjects to confirm their continued 
participation. 
 Prior to initiation of any study -specific procedures, documented IC must be obtained from the subject (or 
their legally authorized representative, US ONLY ). Likewise, privacy or health informat ion protection 
regulation may require subjects to sign additional forms to authorize centers to submit subject 
information to the study sponsor. The IC process must be conducted by [CONTACT_183120] [INVESTIGATOR_353967], and the ICF and the A uthorization to Use and Disclose Personal Health 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657561]  Page 49 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Information/Research Authorization/other privacy language as required by [CONTACT_508777] (or their legally authorized representative, US ONLY ) in a language he/she is able to read and 
understand. The process of IC must be conducted without using coercion, undue or improper influence 
on, or inducement of the subject to participate by [CONTACT_169269]. The informed consent process shall not waive or appear to waive the  subjectâ€™s legal rights. The language 
used shall be as non -technical as possible and must be understandable to the subject and the impartial 
witness, where applicable.  
 The subject must have ample time and opportunity to read and understand the ICF to inquire about 
details of the study, and to decide whether or not to participate in the clinical study. All questions about 
the study should be answered to the satisfaction of the subject. When the subject decides to participate in the clinical study, the ICF and the Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language as required by [CONTACT_508778] (or their legally authorized representative, except in Europe) and eith er 
the Investigator or the Investigatorâ€™s authorized designee, as required by [CONTACT_1769]. If applicable, witness shall also sign and personally date the consent form to attest that the information in the ICF was accurately explained and clearly understood b y the subject, and that IC was freely given.  
 In Europe, include a personally dated signature [CONTACT_3265] [CONTACT_079] [INVESTIGATOR_131418]. The Principal Investigator [INVESTIGATOR_508755].  
 A copy of the ICF and the Authorization to Use and Disclose Personal Health Information/Research  
Authorization/other privacy language as required by [CONTACT_2371], signed and dated as required by [CONTACT_2371], must be  
provided to the subject . 
 
If consent is obtained the same day the subject begins participating in study -related procedures, it must 
be documented in the subjectâ€™s case history that consent was obtained prior to participation in any study 
related procedures. It is best practice for the IC process to be documented in the subjectâ€™s case history, 
regardless of circumstance. In the event the subject cannot read and/or write, a witnessed (impartial 
third party) ICF will be allowed, provided detailed documentation of the process is reco rded in the 
subjectâ€™s case history and the witness signs and dates the ICF  to attest that the information was 
accurately explained and that informed consent was freely given . In Europe, when a subject cannot read 
and/or write, an independent witness shall be present throughout the process, the written ICF and any 
other information shall be read aloud and explained to the prospective subject. The subject should â€œmake 
his markâ€ (sign or otherwise physically mark the document so as to indicate consent) on the ICF as well. 
The ICF should document the method used for communication with the prospective subject and the specific means by [CONTACT_181016].  
 The original of the signed ICF and the Authoriz ation to Use and Disclose Personal Health  
Information/Research Authorization/other privacy language as required by [CONTACT_508779][INVESTIGATOR_307]/clinical chart and/or with the subjectâ€™s study documents. The ICF and the Authorization to Use and Disclose  Personal Health Information/Research Authorization/other privacy language as required by 
[CONTACT_508780]. Any Medtronic Field personnel who support the study procedure must be able to review the subjectâ€™s signed an d dated ICF and verify its completeness 
prior to proceeding with the procedure. In the event the Medtronic Field personnel identify an ICF as 
being incomplete, the study procedure will not be allowed to occur until the consent of the subject can be 
adequately and appropriately obtained.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657562]  Page 50 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 11.4. Randomization and Treatment Assignment  
Enrolled subjects are eligible for randomization after  all inclusion and none of the exclusion criteria are 
met and after the baseline QoL questionnaires are completed .  Subjects will be randomized in a 1: 1 
fashion to undergo a cryoablation procedure (treatment arm) or receive AAD therapy ( control arm).   
See Section 11.5.2  for control arm procedures and Section 11.5.3 for treatment arm procedures.  
Subjects will be randomized using an electronic randomization system .  The randomizatio n schedule will 
be stratified by [CONTACT_508781] 1:1.   
Subjects will be analyzed according to a modified intention -to-treat protocol: subjects who withdraw their 
informed consent prior to the  index cryoablation procedure  or initiation of AAD therapy will be excluded 
from the analysis of the primary safety and efficacy endpoints. Otherwise , the standard intention -to-treat 
protocol is applied: subjects who receive either therapy, regardless of w hat it actually is, will be analyzed 
according to their randomization status.  This allows for the protection of the benefits of randomization, 
while avoiding the problem of attrition and adverse events occurring in the time between randomization 
and the initiation of treatment, which, due to the practicality of scheduling can be up to 30 days.  All 
randomized subjects should be encouraged to comply with the study procedures until study closure.  
11.5. Description of All Study Procedures and Visits  
 Enrollment  & Baseline  11.5.1.
The patient  is considered a subject enrolled in the study  upon completion of the IC process.  The date 
the subject signed the ICF and HIPAA/data  protection  authorization/or  other privacy language  where 
required by [CONTACT_508782] s ubjectâ€™s medical records.  
All baseline assessments must be performed prior to treatment (cryoablation procedure  or initiation of 
AADs). The following evaluations will be performed after the subject signs the ICF, unless previously 
performed as part of routine clinical evaluations within the specified windows:  
Within [ADDRESS_657563] signed the Informed Consent Form: 
â€¢ Trans-thoracic echocardiogram (TTE) for the collection of left atrial size, left ventricular ejection 
fraction, and m itral valve impairment.  A repeat TTE procedure for the purpose of this study is 
not required if a TTE was performed within [ADDRESS_657564] signed the Informed Consent Form, but prior to cryoablation procedure  or AAD 
treatment : 
Note: The time between randomization and the procedure /AAD initiation  must not exceed [ADDRESS_657565]  Page 51 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢ Assessment of all factors specified for evaluation under Inclusion Criteria and Exclusion 
Criteria (Section 10.3 and  10.4), including TTE (required prior to randomization).  
â€¢ EQ-5D and AFEQT  Questionnaires  (required prior to randomization)  
â€¢ Randomization  
â€¢ Demographics  
â€¢ Medical history  
â€¢ Physical examination  
â€¢ CHA2DS2-VASc  Score 
â€¢ Pregnancy screen  (required only for female subjects of childbearing potential)  
o For this study, a woman of childbearing potential is defined as a premenopausal female 
capable of becoming pregnant (not sterilized or post -menopausal).  
â€¢ Review of AF sy mptoms 
â€¢ 12 lead ECG  
â€¢ Review of medications to treat atrial arrhythmias and anticoagulation medications  
â€¢ Transesophageal  Echocardiogram (TEE)  (treatment arm only)  
o TEE must be performed in all subjects who present to the ablation procedure in atrial fibrillation lasting more than 48 hours in duration (or of an unknown duration).  However, the TEE is not required if the subject has adequate systemic anticoagulation that has 
been maintained for at least [ADDRESS_657566] a CHA 2DS2- VASc â‰¥2 and present to the 
procedure with a sub -therapeutic INR (<2.0) or if the subject has had a significant 
interruption of NOACs.   A significant interruption of NOACs is defined as any missed  dose 
within [ADDRESS_657567] be performed within 1 day of the ablation procedure (on the 
day of or within the day prior to ). 
 Control Arm - AAD Initiation  11.5.2.
Subjects must initiate a Class I or III AAD within [ADDRESS_657568] of care; however, amiodarone should only be 
used if other AADs were not tolerated or failed.  The 2014 AHA/ACC/HRS Guideline for the Management 
of Patients with AF  should be consulted for AAD prescriptions .  Modifications to AADs (type or dosage 
increase) may be made for up to [ADDRESS_657569] allowed 
only up to  physiciansâ€™ discretion to guarantee the safety of the patients.   The possible concomitant use of 
beta blockers  can still be optimized after the optimization period.   Reason for AAD modification must be 
documented.   
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657570] is an efficacy failure.   
Treatment failure is defined in section [IP_ADDRESS] . 
 Treatment Arm - Cryoablation Procedure   11.5.3.
Within 30 days of randomization, perform the pulmonary vein isolation procedure using the Arctic Front 
Advanceâ„¢ Cardiac CryoAblation Catheter.  
If needed, a Freezor Â® MAX Cardiac CryoAblation Catheter may also be utilized for gap ablation to 
complete electrical isolation of the pulmonary veins and creation of ablation lines between the inferior 
vena cava and the tricuspid valve.  The Investigator is to perform the procedure according to the 
procedural steps in this CIP and the Instructions for Use for the catheters .  Appropriate  sedation and 
venous access should be attained at the Investigatorâ€™s standard practice according to their institutionâ€™s 
pre-established procedures/guidelines at the time of the procedure.   
The use of any non-study device in the left atrium is not permitted.  
Only the Medtronic FlexCath sheath family should be used with the Ar ctic Front Advance â„¢ Cardiac 
CryoAblation Catheter.  The use of other sheaths may damage the device.  The Investigator may choose 
compatible guidewires and mappi[INVESTIGATOR_54368].  
[IP_ADDRESS].  Esophageal Visualization and Temperature Monitoring  
Ensure an esophageal temperature monito r is used for each cryoablation application.  The cryo application 
must be ceased if the temperature reaches â‰¤  15Â°C. 
[IP_ADDRESS].  Pre-procedure Anticoagulation  
Current recommendations for anticoagulation are found in the 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation (Calkins, et. al. 2012) .
   Anticoagulation 
pre-procedure should  be determined based upon the subjects CHA 2DS2-VASc score . Oral anticoagulants 
are required if the subject has had a prior stroke or TIA, or if the subject has a CHA 2DS2-VASc score â‰¥2.  
When anticoagulation is required, subjects must take it for at least 21 days prior to an ablation 
procedure.  Oral anticoagulants are not required for subjects with nonvalvular AF and a CHA 2DS2-VASc 
score of 0 or 1.  
[IP_ADDRESS].  Intra-procedure Anticoagulation  
Heparin should be administered prior to or immediately following transseptal puncture during AF ablation 
procedures and adjusted to achieve and maintain an ACT of [ADDRESS_657571] 
recommended to be checked at 30 minutes  intervals.  Administration of protamine following ablation to 
reverse heparin should be considered.  
[IP_ADDRESS].  Post-procedure Anticoagulation  
Systemic oral anticoagulation should be initiated on the day of the procedure and is recommended for at least two months following an AF ablation procedure.  Decisions regarding the continuation of systemic 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657572]  Page 53 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 anticoagulation agents more than two months following ablation should be based on the patientâ€™s risk 
factors for stroke as estimated by [CONTACT_370542]2DS2-VASc score and not on the presence or type of AF . 
Discontinuation of systemic anticoagulation therapy post ablation is not recommended in patients who are at high risk of stroke as estimated by [CONTACT_370542]
2DS2-VASc score.  
[IP_ADDRESS].  Diaphragm Movement  
a. Prior to the first cryoablation  application, the Investigator will make a fluoroscopic recording 
of inspi[INVESTIGATOR_508756]. 
b. Continuous phrenic nerve pacing with abdominal palpi[INVESTIGATOR_332] m ust be performed for all right 
pulmonary vein cryoapplications and should  be considered for all cryoapplications .  
Additional methods of phrenic n erve monitoring are encouraged, such as diaphragmatic 
compound motor action potential (CMAP) . 
c. After the last cryoablation application, the Investigator will make a fluoroscopic recording of inspi[INVESTIGATOR_508756].  
[IP_ADDRESS].  Balloon Pulmonary Vein (PV) Cryoablation  
a. Every effort consistent with subject welfare will be made to treat all PVs or their anomalous equivalents. 
b. The catheter will be advanced into the left atr ium over the mappi[INVESTIGATOR_508757].  Once inflated, the catheter will be tracked over the Achieveâ„¢ catheter and 
positioned at the entrance of the PV.  
c. Assess the positioning, contact [CONTACT_508783]â€™s balloon by 
[CONTACT_508784], ultrasound imaging, or other technique.  Reposition as 
needed. 
d. Each pulmonary vein must be assessed for entrance block and, where assessable, exit block 
to demonstra te electrical isolation.  
e. It is recommended that the Investi gator use cryoapplications of three (3) minutes each.  
Once PV isolation has been achieved, one (1) additional application of three (3) minutes at 
the same PV should be performed; 
however, it is up to the operatorâ€™s discretion to assess 
application time an d necessity of the additional freeze  given factors such as time to 
isolation of prior  application(s) , temperature of prior application(s) , risk of collateral 
damage, etc.  
f. Upon the Investigatorâ€™s assessment of procedure completion, isoproterenol and/or 
adenosine may be used to assess pulmonary vein isolation.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657573]  Page 54 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  Other Ablations During Index Procedure  
a. Ablation of  the cavotricuspid isthmus is required in subjects with a history of typi[INVESTIGATOR_508758].  Complete an assessment for 
bi-directional block if  this procedure is performed.  Any commercially released catheter 
deemed appropriate for the procedure may be used.  
 
b. The following are not allowed:  
o Left atrial non -PVI ablations including but not limited to, ablation of linear lesions, 
complex fractionated electrograms or non -PV triggers  
o Ablation using any non- study device  in the left atrium  
[IP_ADDRESS].  Cardioversion  
a. Electrical or pharmacological cardioversion to sinus rhythm must be att empted following the 
PVI portion of the procedure if sinus rhythm wasnâ€™t restored.  Cardioversion may be 
performed prior to PVI if needed.  
[IP_ADDRESS].  Procedure Documentation  
During the procedure the investigator will document the following:  
â€¢ Catheter s used (i.e. Arc tic Front Advance â„¢, Freezor Â® MAX and Achieve â„¢ Mappi[INVESTIGATOR_54370], 
etc.) 
â€¢ Minimum temperature for each cryoapplication  
â€¢ Duration of each cryoapplication  
â€¢ Vein location for each cryoapplication (e.g. right superior PV) 
â€¢ Use of phrenic nerve pacing or other phrenic nerve monitoring technique for each 
cryoapplication, specifically those cryoapplications surrounding the RS and RI PVs 
â€¢ Demonstrated electrical block and, if real-time signals are available, time to isolation  
â€¢ Adjunctive catheters, mappi[INVESTIGATOR_54371], sedation type, procedure information, 
esophageal temperature, ACT, cardioversion use and fluoroscopy time will be collected . 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657574]  Page 55 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Hospi[INVESTIGATOR_3849]  11.5.4.
At or shortly before hospi[INVESTIGATOR_2345], the following will be performed and collected:  
a. Adverse event assessment  
b. In the case of suspected PV stenosis, Magnetic Resonance Imaging (MRI) or 
Computerized Tomography Scanning (CT scan) is required.  
c. Review medications 
d. [ADDRESS_657575] X-ray:  For any subject whose p ost-procedural fluoroscopy demonstrated 
study-related PNI, a follow -up chest X- ray, including inspi[INVESTIGATOR_508759], 
will be performed  
f. Review study requirements with the subject to help ensure compliance with follow -
up procedures  
g. Evaluate the subjectâ€™s neurological status per institutional standard of care to 
determine if a formal neurological consultation  should be performed  for stroke 
assessment.  Report any adverse events that result from the neurologic evaluation  
and consultation, if applicable .   
 Medication Compliance  11.5.5.
Information regarding medications prescribed for anticoagulation or to treat atrial arrhythmias will be 
collected through study exit.  The following information will be collected for medications to treat atrial 
arrhythmias:  medication name, purpose for use, start and stop dates, dose, dosage changes  (and 
reasons for changes) , and route of administration.  Data collection for anticoagulation medication will be 
limited to medication name [CONTACT_508807].   
Control Arm (AAD):    
Subjects must initiate a Class I or III AAD within [ADDRESS_657576] of care; however, amiodarone should only be 
used if other AADs were not tolerated or failed.  The 2014 AHA/ACC/HRS Guideline for the Management 
of Patients with AF  should be consulted for AAD prescriptions .  Modifications to AADs (type or dosage  
increase) may be made for up to [ADDRESS_657577] allowed only up to  physiciansâ€™ discretion to guarantee the safety of the patients.   The possible concomitant use of 
beta blockers  can still be optimized after the  optimization period.  
Cryoablation (Treatment Arm) : 
Per physician discretion, class I or  III antiarrhythmic , including sot alol, medication use is permitted for up 
to [ADDRESS_657578] two months followi ng an AF ablation procedure.  Decisions regarding the continuation of systemic 
anticoagulation agents more than two months following ablation should be based on the patientâ€™s risk factors for stroke as estimated by [CONTACT_370542]
2DS2-VASc score and not on the pre sence or type of AF.   
Discontinuation of systemic anticoagulation therapy post ablation is not recommended in patients who 
are at high risk of stroke as estimated by [CONTACT_370542]2DS2-VASc score . 
 
All Subjects : 
All other medications (those that are not specified above ) are permitted in the study , with the exception 
of investigational drugs that may confound the study results.  Beta-blockers may be prescribed per 
standard of care.   
 Subsequent Ablation Procedures  11.5.6.
Any subsequent a blation in the left atrium or AF surgery will be counted as an endpoint failure.  There is 
no 90 day blanking period for repeat ablation.  Subsequent ablations and AF surgeries will be 
documented on an eCRF.  
Subsequent ablations  in the right atrium  are allowed (e.g. typi[INVESTIGATOR_502906]) . 
 Cardioversions  11.5.7.
Electrically and pharmacologically cardioverting the subject to sinus rhythm is allowed in the [ADDRESS_657579] -
procedure blanking period (treatment arm)/AAD optimization period (control arm) at the discretion of the 
Investigator.   Electrically or pharmacologically cardioverting the subject to sinus rhythm after the 
blanking period /AAD optimization period will be counted as an efficacy endpoint failure.   
 Scheduled Follow -up Visits  11.5.8.
After the index cryoablation procedure  (treatment arm) or AAD initiation (control arm)  is reported in the 
study database, the database will calculate the target dates and windows for each visit to the site. Should 
a subject miss a visit or the visit fall outside the pre -specified window, a study deviation must be reported 
and the original follow -up schedule maintained for subsequent visits.  
Data analyses include follow -up visits, regardless of whether the vi sit occurs within the window.  
Therefore, a late visit is preferred over a missed visit but must be accompanied by a deviation . Follow-up 
visit windows are listed in Table [ADDRESS_657580]  Page 58 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  Three Month Office Visit  
â€¢ Review medications  
â€¢ Adverse event assessment  
â€¢ Review symptoms suggestive of recurrent AF/AT/AFL  
â€¢ Health care utilization assessment - collect information about hospi[INVESTIGATOR_508760]  
â€¢ 12 lead ECG  
â€¢ Provide the subject  with patient -activated ambulatory monitoring equipment ; provide instructions  
for and weekly and symptomatic transmissions. 
â€¢ Chest X-ray 
o For any subject whose post -procedural fluoroscopy demonstrated study -related PNI, a 
follow-up chest X- ray, including inspi[INVESTIGATOR_508759], will be performed if the 
PNI was unresolved at the one month visit  
â€¢ In the case of suspected PV stenosis, Magnetic Resonance Imaging (MRI) or Computerized 
Tomography Scanning (CT scan) is required.  It is not required at this visit if it was already completed at an earlier visit and PV stenosis was confirmed.   
[IP_ADDRESS].  Six Month Office Visit  
â€¢ Review medications  
â€¢ Adverse event assessment  
â€¢ Review symptoms suggestive of recurrent AF/AT/AFL  
â€¢ Health care utilization assessment - collect informa tion about hospi[INVESTIGATOR_508760]  
â€¢ 12 lead ECG  
â€¢ 24h continuous ECG monitoring with ambulatory monitoring equipment  
â€¢ EQ-5D and AFEQT Questionnaire s 
â€¢ Review the patient-activated ambulator y monitoring instructions with the subject .   
â€¢ Chest X-ray, including inspi[INVESTIGATOR_508759], is required for subjects whose PNI was 
unresolved at the 3 month visit 
â€¢ In the case of suspected PV stenosis, Magnetic Resonance Imaging (MRI) or Computerized Tomography Scanning (CT scan) is required.  It is not required at this visit if it was already 
completed at an earlier visit and PV stenosis was confirmed.   
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657581]  Page 59 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  Twelve month Office Visit  
â€¢ Review medications  
â€¢ Adverse event assessment  
â€¢ Review symptoms suggestive of recurr ent AF/AT/AFL  
â€¢ Health care utilization assessment - collect information about hospi[INVESTIGATOR_508760]  
â€¢ 12 lead ECG  
â€¢ 24h continuous ECG monitoring with ambulatory monitoring equipment .  The subject will be 
instructed to apply the continuous monitoring patches and complete the [ADDRESS_657582] is not able to apply 
the device prior to the visit, it may be applied by [CONTACT_508785] 12 month visit.   
â€¢ EQ-5D and AFEQT Que stionnaires 
â€¢ Collect the ambulatory monitoring equipment and return to Medtronic (or designee).  If the 
subject did not perform the continuous monitoring prior to the [ADDRESS_657583] instructions on how to 
return the equipment.   
â€¢ Chest X-ray, including inspi[INVESTIGATOR_508759], is required for subjects whose PNI was 
unresolved at the 6 month visit  
â€¢ In the case of suspected PV stenosis, Magnetic Resonance Imaging (MRI) or Computerized 
Tomography Scanning (CT scan) is required.  It is not required at this visit if it was already completed at an earlier visit and PV stenosis was confirmed.   
â€¢ Inform the subject they have completed the study 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657584]  Page 60 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Unscheduled Office Visits  11.5.9.
An unscheduled visit is defined as any unplanned cardiovascular-related office visit at the study site  that 
is performed by [CONTACT_508786].  Submit to 
the core lab any 12 lead ECG or conti nuous monitoring completed in conjunction with an unscheduled 
office visit.  The following information is required to be collected at unscheduled follow -up visits:  
â€¢ Review medications  
â€¢ Adverse event assessment  
â€¢ Review symptoms suggestive of recurrent AF/AT/AFL  
â€¢ Health care utilization assessment - collect information about hospi[INVESTIGATOR_508760]  
â€¢ 12 lead ECG  
 Re-Ablation/Crossover Ablation  11.5.10.
â€¢ Obtain approval from Medtronic for crossover ablations (not required for treatment arm 
reablation) 
â€¢ Perform the following assessments prior to the cryoablatio n: 
o Review medications  
o Adverse event assessment  
o Review symptoms suggestive of recurrent AF/AT/AFL  
o EQ-5D and AFEQT Questionnaire s 
o Health care util ization assessment - collect information about hospi[INVESTIGATOR_508761]  
â€¢ Procedure Data:  
o Catheter s used (i.e. Arctic Front Advance â„¢, Freezor Â® MAX and Achieve â„¢ Mappi[INVESTIGATOR_169240], etc .) 
o Minimum temperature for each cryoapplication  
o Duration of each cryoapplication  
o Vein location for each cryoapplication (e.g. right superior PV) 
o Use of phrenic nerve pacing or other phrenic nerve monitoring technique for each 
cryoapplication, specifically tho se cryoapplications surrounding the RS and RI PVs  
o Demonstrated electrical block and, if real -time signals are available, time to isolation  
o Adjunctive catheters, mappi[INVESTIGATOR_54371], sedation type, procedure information, esophageal temperature,  ACT, cardioversion use and fluoroscopy time will 
be collected  
o Pulmonary vein isolation stats from previous ablation (re -ablations only)  
 [ADDRESS_657585]  Page 61 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Ambulatory Monitoring  11.5.12.
Market- released ambulatory monitoring equipment will be distributed by a core lab to centers after 
activation has occurred.  Subjects will be provide d with a small patient-activated electronic ambulatory 
monitoring device after the AAD optimization (contr ol arm) or post -ablation blanking period (treatment 
arm) ends.  This device will serve two functions:  
â€¢ 24 hour continuous monitoring :  This is tradition ally done using a Holter monitor .  The 
investigative site personnel will apply the d evice patches for the subject during the subjectâ€™s [ADDRESS_657586] will be asked to apply the 
continuous monitoring pat ches themselves prior to the 12 month study visit .  Additionally, 
subjects may be asked to perform 2 4 hour continuous monitoring on their own if they miss a 
scheduled study visit.   
â€¢ Patient-activated mode:  Subjects will be asked to transmit ECG data weekly and whenever they 
experience AF symptoms.   This mode does not require adhesive patches; the subject simply 
holds the device to his or her chest for a short period of time.   
In both modes, t he data automatically transmits to the core lab via a secured cell phone connection.     
The core lab will manage maintenance, calibration and tracking of the ambulatory monitoring equipment. 
The core lab will be responsible for adjudication of rhythm documentation  for the primary  efficacy 
objective of the study.  The core lab will send the results of all ambulatory monitoring  analyses to the 
Investigators for appropriate follow -up, if necessary , and assessment for adverse event reporting . 
Subjects will return the ambulatory monitoring equipment at  the [ADDRESS_657587]  Page 62 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 documents, and any discrepancies shall be explained in writing.  The eCRF may be considered source 
for the foll owing data collection elements:  
â€¢ Time of isolation of the cryoablation catheter  
â€¢ Esophageal temperature 
â€¢ Investigator assessment of adverse event or death relatedness and severity  
â€¢ Date center became aware of the adverse event, device deficiency or death  
â€¢ Reason for study deviation  
â€¢ Database generate d patient reference ID  
When copi[INVESTIGATOR_41090] -outs of the source documents are  made, center personnel must sign and date 
any copi[INVESTIGATOR_54385] a statement that this is complete and true  
reproduction of the original source document.   The sponsor or a regulatory authority may audit or 
inspect the st udy center to evaluate the conduct of the  study.  
The clinical Investigator(s)/institution(s) shall allow study related monitoring, audits, IRB /EC review 
and regulatory inspection by [CONTACT_20618]/documents.   Further detail on 
data management is provided in Section  17.3. 
11.9. Deviation  Handling  
A study deviation is defined as an event within the study that did not occur according to requirements 
specific to the CIP or CTA . Every attempt must be made to avoid study deviations.  Prior approval by 
[CONTACT_508787], contemplates, or makes a 
conscious dec ision to deviate. In countries following ISO [ZIP_CODE]:2011, prior approval for study deviations 
will be reported to local authorities and ethics boards per local requirements.  If the deviation affects 
subjectâ€™s rights, safety and well- being, or the scientifi c integrity of the study, prior approval from ethics 
board and/or competent authority (CA) is also required, depending on local legislations. Prior approval is not required when a deviation is necessary to protect the safety, rights, or well-being of a sub ject in an 
emergency or in unforeseen situations beyond the Investigatorâ€™s co ntrol (e.g. subject failure to a ttend 
scheduled follow -up visits, inadvertent loss of date due to computer malfunction, inability to perform 
required procedures due to subject illness). Subjectsâ€™ failure to submit ambulatory monitoring transmissions per the CIP do not require a deviation to be reported.  Ambulatory monitoring transmission compliance will be tracked by [CONTACT_508788].   
For medically justifiable conditions which preempt a subjectâ€™s ability to complete a study required procedure, it may be permitted to report only one deviation which will apply to all visits going forward.  
This may also apply for other unforeseen situations (e.g. the subject per manently refuses to complete a 
study required procedure and the data will not contribute to the primary endpoint analysis.). However, 
prior approval from Medtronic is required for such situations.  
All study deviations must be reported to Medtronic regardless of whether they are medically justifiable, pre-approved by [CONTACT_13735], an inadvertent occurrence, or taken to protect the subject in an emergency.   
The description of the deviation and justification must be documented and submitted to Medtronic via eCRF completion.   
 
In the event the deviation involves a failure to obtain a signed Informed Consent Form, or is made to 
protect the life or physical well- being of a subject in an emergency, the deviation must be reported to the 
IRB/EC as well as Medtronic within five (5) working days.  Reporting of all other study deviations should 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657588]  Page 63 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 comply with IRB/EC policies and/or local laws and must be reported to Medtronic as soon as possible 
upon the site becoming aware of the deviation.  Refer to  
Table 9 for reporting requirements.  
Medtronic is responsible for reviewing deviations, assessing their significance , and identifying any 
necessary corrective and/or preventive actions  (e.g. amend the CIP, conduct additional training, and 
terminate the investigation) .  Repetitive or serious Investigator compliance issues may result in  initiation 
of a corrective action pl an with the Investigator and center, and in some cases , may necessitate 
suspending a centerâ€™s ability to enroll until the problem is resolved, or ultimately terminating the 
Investigatorâ€™s participation in the study . Medtronic will provide center -specific r eports to Investigators 
summarizing information on deviations that occurred at the investigational center on a periodic basis.  
11.10.  Subject Withdrawal or Discontinuation  
A subject can withdraw from the study at any time.  If the subject wishes to exit from the study (i.e. the 
subject revokes consent), the center is required to document the reason for exit on an eCRF.  In addition, 
centers shall follow the regulations set forth by [CONTACT_11577]/EC. 
Prior to exiting a subject from the study, it is recommended to fo llow the subject until all ongoing device 
and/or procedure related adverse events are resolved or unresolved with no further actions planned.  An unscheduled office visit should be attempted if the subject exits the study outside of a scheduled follow -
up visit. 
Following exit, subjects will continue to receive standard medical care.  Upon exiting from the study, no 
further study data will be collected or study visits will occur for the subject.  All data available through the 
time of the subjectâ€™s exit will  be used for analysis.  
Reasons for subject withdrawal or discontinuation include:  
â€¢ Subject is lost to follow -up 
â€¢ Subject did not meet inclusion/exclusion criteria after the date the subject signed the Informed 
Consent Form  and prior to randomization.  
â€¢ The subject was randomized to the treatment arm, but n o cryoballoo n ablation procedure was 
attempted  
â€¢ The subject was randomized to the control arm, but no AAD was initiated  
â€¢ Subject chooses to withdraw (e.g., Informed Consent Form  withdrawal, relocation to another 
geographic location)  
â€¢ Investigator deems withdrawal necessary (e.g., medically justified, inclusion/exclusion criteria not 
met, failure of subject to maintain adequate study compliance)  
â€¢ The sponsor  or regulatory authority  decides the study will be close d or a pa rticular center will be 
closed 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657589]  Page 64 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 The following information is required to be collected at early study exit:  
â€¢ Reason for exit must be documented on the eCRF and in the subjectâ€™s medical record  
â€¢ An unscheduled office visit should be attempted if the subject exits the study outside of a 
scheduled follow -up visit 
In the case that the subject is determined to be lost to follow -up, details of a minimum of two attempts 
and the method of attempt (e.g., one letter and one phone record or two letters) to contact [CONTACT_508789].  In addition, follow the regulations set forth by [CONTACT_114021] /EC. 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657590] -market surveillance. 
The residual risks associated with the Arctic Front Advance â„¢ Cardiac CryoAblation Catheter have  been 
found to be acceptable and have been mitigated to the fullest ex tent possible. The potential benefits 
related to the use of the Arctic Front Advanc eâ„¢ Cardiac CryoAblation Catheter  have been determined to 
outweigh any potential risks.  The device has never been recalled.  
There are potential risks and side effects associated with ablation procedures.  The Investigator shall 
describe risks in further detail when asked by [CONTACT_423].  The risks must be continuously monitored, 
assessed and documented by [CONTACT_737].  The risks associated with the cryoablation procedure  are 
listed below.   
â€¢ Anemia-deficiency of red blood cells or of hemoglobin in the blood resulting in weariness.  
â€¢ Anxiety-a feeling of worry, nervousness, or unease.  
â€¢ Back pain- pain felt in the lower or upper back . 
â€¢ Bleeding e.g. bleeding into the retroperitoneal space.  
â€¢ Bronchitis, cough, pneumonia -inflammation of the lungs can be caused by a virus or bacteria . 
â€¢ Cardiac tamponade -pressure on the heart as a result of fluid collecting in the sac surrounding the  
heart. 
â€¢ Cardiopulmonary arrest -cessation of blood circulation and/or respi[INVESTIGATOR_508762]/or lungs.  
â€¢ Chest discomfort/pain/pressure -includes a range of feeling from sharp stabbing to dull ache in 
the chest.  
â€¢ Cold feeling -having a low or inadequate temperature.  
â€¢ Complicatio ns associated with contrast agents -adverse effects of contrast agents used during the 
procedure (e.g. allergic reaction or radio contrast nephropathy).  
â€¢ Complications associated with medications commonly utilized during the procedure -known risks 
of medicati ons commonly used during the procedure (e.g. narcotics, anxiolytics, other pain 
medications, anti -vasospasm agents).  
â€¢ Complications at catheter insertion site in the groin:  
o AV fistula -an abnormal connection between an artery and a vein (i.e., cause by [CONTACT_508790] e 
insertion through the femoral artery and vein).  
o Hematoma/Bruising- a collection of blood in the tissue surrounding the catheter insertion 
site. 
o Infection -localized redness, heat swelling and pain at the catheter insertion site.  
o Pain-discomfort at the cath eter insertion site that can range from mild to severe.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657591]  Page 66 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 o Pseudoaneurysm -a collection of blood in the tissue surrounding the catheter insertion site 
due to ongoing leaking of blood from a blood vessel.  
o Significant bleeding -blood loss from the catheter insert ion site requiring surgery or 
transfusion of 2 or more units of packed red blood cells (PRBCs).  
â€¢ Coronary artery spasm, vasospasm -constriction of a blood vessel.  
â€¢ Death-a complication or deterioration of health ultimately leading to a patientâ€™s death.  
â€¢ Dissection of a blood vessel -a tear within the wall of  a blood vessel.  
â€¢ Dizziness, lightheadedness- feeling faint, woozy, weak or unsteady.  
â€¢ Embolism- formation and dislodgement of a blood clot (thrombus) or dislodgement of 
cholesterol/plaque within the blood vessel, which travels downstream into small vessels, blocking 
blood flow and causing temporary or permanent damage to organs distal to blockage.  Emboli are known to cause myocardial infarction, transient ischemic attack, stroke/cardiovascular 
accident, blurred vision, visual changes, paralysis, paresis,  or kidney damage, peripheral ischemia 
and may ultimately lead to incapacitation or death.  Symptomatic and non -symptomatic.  
â€¢ Endocarditis â€“ inflammation of the inner surface of the heart.  
â€¢ Esophageal injury â€“damage to your swallowing tube, atrio- esophageal fistula - abnormal 
passageway between the heart and esophagus, hematemesis (vomiting blood).  
â€¢ Fatigue- extreme tiredness.  
â€¢ Fever- abnormally high body temperature.  
â€¢ Gastroparesis- delayed gastric emptying.  
â€¢ Headache - pain in the head.  
â€¢ Heartblock requiring permanent pacemaker implantation  
â€¢ Heart rhythm disturbances -disruption of normal heart rate or rhythm  (e.g. atrial flutter, 
tachycardia, bradycardia).  
â€¢ Hemothorax â€“collection of blood around the lungs.  
â€¢ Hiccups- involuntary spasm of the diaphragm and respi[INVESTIGATOR_54374].  
â€¢ Hypertension- high blood pressure.  
â€¢ Hypotension -low blood pressure.  
â€¢ Injury to lung - (e.g. bronchial lesion, hemoptysis, constriction, pulmonary hemorrhage, bronchia 
fistula). 
â€¢ Mild skin discomfort or irritation- redness sensitivity of the skin cause during or after the 
procedures (e.g. electrodes used with the ECG and Holter recorder might cause mild skin discomfort or irritation or some skin discomfort following electrode removal or tape removal).  
â€¢ Nausea-a sensation of unease and discomfort in the upper stomach with an urge to vomit.  
â€¢ Perforation of a blood vessel  or cardiac tissue -unintended puncture through the wall of a blood 
vessel or cardiac tissue . 
â€¢ Pericardial effusion - fluid collecting in the sac that surrounds the heart.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657592]  Page 67 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢ Pericarditis â€“ inflammation of the sac that surrounds the heart.  
â€¢ Phrenic nerve injury â€“damage to the nerve that controls breathing.  
â€¢ Pleural effusion â€“ collection of extra fluid around the lungs.  
â€¢ Pulmonary edema - excess fluid in the lungs. 
â€¢ Pulmonary hypertension - high blood pressure that affects the arteries in the lungs and the right 
side of the heart.  
â€¢ Pulmonary vein hematoma - trauma to the pulmonary vein.  
â€¢ Pulmonary vein stenosis â€“ blockage in the blood vessels takes blood from the lu ngs to the heart.  
â€¢ Pneumothorax â€“ collapsed lung.  
â€¢ Renal dysfunction -kidneys fail to adequately filter waste  products from the blood.  
â€¢ Right sided heart failure - right side of the heart is not pumpi[INVESTIGATOR_508763].  
â€¢ Shivering - body shaking.  
â€¢ Shortness of breath- difficulty breathing.  
â€¢ Small ischemic cerebral (brain) lesions not accompanied by [CONTACT_508791].  So far,  the relationship 
between these lesions an d an increased incidence of stroke or transient ischemic attack (a mini 
stroke) has not been established.  However, whether these lesions will result in long term 
cognitive decline (e.g. loss of memory and trouble thinking) is unclear.  
â€¢ ST elevation - the ST segment of an ECG is abnormally high above the baseline.  
â€¢ Sore throat - pain in the throat.  
â€¢ Urinary infection - an infection in the urinary system.  
â€¢ Vascular complications requiring surgery -damage to an artery (e.g. femoral) or vein requiring 
surgical repair.  
â€¢ Vasovagal reaction - reflex of the involuntary nervous system that causes the heart to slow down 
and blood pressure drops.  
â€¢ Vomiting- forceful expulsion of stomach contents through the mouth and/or nose.  
The risks of participating in this clinical study are the same as the cryoablation procedure risks, and also 
include: 
â€¢ Risks/discomforts associated with sedation/anesthesia:  
o Hoarseness. 
o Myalgia (pain in the muscles).  
o Numbness and tingling of the fingers.  
o Diarrhea.  
o Dry mouth.  
o Sleepi[INVESTIGATOR_008]. 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657593]  Page 68 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢ Radiation exposure due to potential for additional CT /MRI scan or Chest X- rays. 
â€¢ Patches and adhesive used with the ambulatory monitoring equipment may cause skin discomfort 
or irritation, or some skin discomfort following patch removal.  
12.2. Risk Minimization  
Medtronic has attempted to minimize the potential risks to subjects in this study by [CONTACT_54432]: 
â€¢ Selecting qualified investigators and training study personnel on the CIP . 
â€¢ Requiring that investigators be active ly involved in the procedure and follow -up of the subjects 
who undergo a study procedure . 
â€¢ Providing guidelines for subject selection and evaluation . 
â€¢ Requiring that subjects be followed at regular intervals following the ablation procedure to 
monitor for re currence of atrial arrhythmias and to assess for adverse events . 
12.3. Potential Benefits  
The Arctic Front  AdvanceTM Cardiac CryoAblation Catheter may reduce or eliminate atrial fibrillation in 
subjects who have not yet failed an AAD; however, some subjects may not receive this benefit.  The 
information gained from the study could result in improved management of atrial fibrillation.  It is 
possible that subjects will experience no benefit from participating in the study.  
12.4. Risk-Benefit Rationale  
The cohort of subj ects for inclusion in the study is symptomatic as a result of their atrial fibrillation, but 
has not yet tried AAD therapy.  Cryoablation therapy offers the opportunity to reduce the epi[INVESTIGATOR_508764] o r experience the side effects of AAD therapy.  
In the US, there are no ablation catheters approved to treat subjects with paroxysmal atrial fibrillation 
who have not yet attempted AAD therapy.  If successful, this study could demonstrate meaningful 
therapeu tic benefit in this patient population and provide patients with additional treatment options 
earlier in disease progression.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657594]â€™s participation in the study:  
â€¢ All procedure related AEs  
â€¢ All cryoablation system related AEs  
â€¢ All AAD related AEs  
â€¢ All cardiovascular related AEs 
â€¢ All Serious Adverse Events (SAEs), regardless of relatedness  
Reporting of these events to Medtronic will occur on an Adverse Event (AE) Form, including a description 
of AE, date of onset of AE, date of awareness of site, treatment, resolution, assessment of both the 
seriousness and the r elatedness to the investigational device.  
Each AE must be recorded on a separate AE Form. Exceptions include:  
â€¢ Documented pre -existing conditions are not considered AEs unless the nature or severity of the 
condition has worsened.   Additionally, arrhythmia epi[INVESTIGATOR_508765].  
â€¢ Unavoidable Adverse Events, listed in section 13.[ADDRESS_657595]- procedure.  
â€¢ Cardioversions (DC or Drug) for recurrent symptomatic atrial fibrillation and other atrial 
arrhythmia s are not conside red serious adverse events . 
For any changes in status of a previously reported adverse event (i.e. change in actions taken, change in 
outcome, change in relatedness), an update to the original AE must be provided .  All adverse events 
must be followed until  the adverse event has been resolved, is unresolved with no further actions 
planned, the subject exits the study or until study closure, whic hever occurs first.  
In the event that a subject is exited from the study prior to study closure, all efforts should  be made to 
continue following the subject until all unresolved procedure or cryoablation system related adverse 
events, as classified by [CONTACT_093], are resolved or they are unresolved w ith no further actions 
planned.  
At the time of study exit, all adverse events with an outcome of â€œUnresolved, further actions or treatment plannedâ€ must be reviewed and an update to the original AE must be reported.  At a minimum, if there 
are no changes to the description, relatedness, test and procedures or actions taken, the outcome must 
be updated to reflect â€œUnresolved at time of study closure.â€  
Subject deaths are also required to be reported. Refer to  section 13.3.[ADDRESS_657596] Death collection and 
reporting requirements.  
 Device Deficiencies  13.2.1.
Device deficiency (DD) information will be collected throughout the study and reported to Medtronic. 
Note that device deficiencies that result in an adverse device effect (ADE) to the subject should be 
captured as an Adverse Event only.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657597]  Page 78 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢ Date of death  
â€¢ Detailed description of death  
â€¢ Cause of death  
â€¢ Relatedness to device and/or procedure  
â€¢ Death summary/hospi[INVESTIGATOR_1097] (if available and allowed by [CONTACT_54443]/local law)  
â€¢ Autopsy report (if available and allowed by [CONTACT_54443]/local law)  
â€¢ Death certificate (if available and/or allowed by [CONTACT_54443]/local law)  
[IP_ADDRESS].  Death Classification and Reporting  
Sufficient information will be required in order to properly classify the subjectâ€™s death.  The Investigator 
shall classify each subject death per the following definitions:  
â€¢ Cardiac Death : A death directly related to the electrical or mechanical dysfunction of the heart.  
â€¢ Sudden Cardiac Death (SCD):  Natural death due to cardiac causes, indicated by [CONTACT_54444]; preexisting heart disease may 
have been known to b e present, but the time and mode of death are unexpected. If time of 
onset cannot be determined, SCD will alternativ ely be defined as any unexpected cardiac death 
occurring out of the hospi[INVESTIGATOR_54381].  
â€¢ Non-sudden Cardiac  Death: All cardiac deaths that are not classified as sudden deaths, including 
all cardiac deaths of hospi[INVESTIGATOR_54382].  
â€¢ Non-cardiac Death : A death not classified as a cardiac death.  
â€¢ Unknown Classification : Unknown death classificat ion is intended for use only when there is 
insufficient or inadequate info rmation to classify the death.  
The CEC will review deaths and provide a final adjudication of the primary cause of death and cardiac 
classification. 
Regulatory reporting of subject deaths will be completed according to local regulatory requirements.  
 Product Complaints  13.3.2.
For devices that are market -released, product complaint reporting is applicable.  This includes when an 
AE is related to a market- released device during the study.  The reporting of product complaints is not 
part of the clinical study and should be done in addition to the Adverse Event reporting requirements.  
Refer to local regulations for reporting requirements.  
Product Complaint: Any written, electronic or oral communi cation that alleges deficiencies related to the 
identity, quality, durability, reliability, safety, effectiveness or performance of a medical device that has 
been placed on the market.  
It is the responsibility of the investigator to report all product complaint(s) associated with a medical device distributed by [CONTACT_13735], regardless whether they are related to intended use, misuse or abuse of the product.  Reporting must be done immediately and via the regular channels for market -released 
products.  
Medtronic will notify the regulatory authorities (e.g. FDA) as applicable for the following incidents 
immediately upon learning of them:  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657598]  Page 79 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢ Any malfunction or deterioration in the characteristics and/or performance of a device, as well as 
any inadequacy in the labeling or instructions for use which led or might have led to the death or 
serious deterioration in the st ate of health of a patient, user, or other person.  
â€¢ Any technical or medical reason resulting in withdrawal of a device from the market by [CONTACT_13989].  
â€¢ A serious deterioration in the state of heath includes:  
o Life-threatening illness or injury  
o Permanent impairment of a body function or permanent damage to a body structure 
o A condition necessitating medical or surgical intervention to prevent perma nent 
impairment of a body function or permanent damage to a body structure  
The investigator and Medtronic must abide by [CONTACT_508792] 7. 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657599]  Page 80 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 14. Data Review Committees  
At regular intervals, an independent Clinical Events Committee (CEC) will review and adjudicate all 
reported adverse events and  deaths for subjects participating in the study.  
The CEC will consist of a minimum of three (3) non -Medtronic employed physicians that are not 
participating Investigators for the study, including a CEC chairperson.  
Medtronic personnel may facilitate and participate in a CEC meeting but will be non -voting members.  
For adverse events and deaths reviewed by [CONTACT_15741], Medtronic will provide the CEC with the 
Investigatorâ€™s description and classification.  The CEC is responsible for reviewing the Investigatorâ€™s 
assessment and supportive documentation (when available), reviewing applicable definitions, and 
determining  final classifications for all adjudication parameters.  Additionally, the CEC will provide an 
adjudication of the death classification for all reported deaths including primary cause of death and cardiac classification.  
If the CEC disagrees with the Investigatorâ€™s classification of the event, the rationale will be provided to 
the Investigator. If the Investigator agrees with the CECâ€™s adjudication, the eCRF documenting the event 
will be updated accordingly.  
If the Investigator does not agree with the CECâ€™s adjudication classification, both determinations will be provided within the final report; however, the CECâ€™s adjudication will be used for data analysis.  The 
disagreement will also be included in reporting to IRB and regulatory authorities, if required.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657600]  Page 81 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 15. Statistical Design and Methods  
Medtronic employees will perform all statistical analyses.  
Additionally, a separate Statistical Analysis Plan (SAP) will be developed to further describe statistical 
methods, pre -specified data handling rules (including ho w missing data will be handled) , and pre -
specified analyses, including subgroup analyses, that will be included in study reports (e.g. PMA report, final study report).  Any deviation from the pre -specified statistical analyses will be noted in the study 
report.  
The SAP will include a comprehensive description of the statistical methods and analyses to be included 
in reports that include analysis of endpoints.  Any change to the data analysis methods described in the 
CIP will require an amendment to the C IP only if it changes a principal feature of the CIP.  Any other 
change to the data analysis methods described in the CIP, and the justification for making the change, 
will be described in the clinical study report.  
Additional exploratory analyses of the data may be conducted as deemed appropriate.  
All objectives will be analyzed once all treated subjects  complete the [ADDRESS_657601] exited the study . No interim analyses are planned.  
The primary analysis will be conducted using a modified intent -to-treat protocol; all subjects for whom 
either AAD or cryoballoon ablation therapy is initiated will be analyzed according to their randomization status. Subjects who withdraw consent between randomization and initiation of therapy will be excluded 
from the primary efficacy analysis.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657602]  Page 82 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 15.1. Primary  Efficacy  Objective  
Demonstrate the superiority of cryoballoon ablation as compared to AAD ther apy in terms of the rate of 
freedom from AF/AT/AFL in a non -drug refractory paroxysmal AF population.  
 Hypothesis  15.1.1.
The hypothesis test used in assessment of the  primary efficacy objective is that the proportion of subjects 
with treatment success at [ADDRESS_657603] with Î± = 0.05:  
H0: Ï€cryo = Ï€AAD 
Ha: Ï€cryo â‰ Ï€AAD  
Where Ï€ cryo and Ï€ AAD  are the proportion of treatment successes at [ADDRESS_657604] is considered  a treatment failure if he/she experiences any of the foll owing: 
 
â€¢ Acute procedural failure  (defined in section  [IP_ADDRESS]; treatment arm only)  
â€¢ Documented AF/AT/AFL on ambulatory monitoring/[ADDRESS_657605] -ablation 
blanking period (treatment arm) /AAD optimization period (control arm).  
o Minimum of  30 seconds on ambulatory monitoring or 10 seconds on 12 -lead ECG.  
o Note: Documented occurrence and treatment of typi[INVESTIGATOR_169244] -sided cavotricuspid isthmus 
dependent atrial flutter is not considered a failure if confirmed by [CONTACT_508793] t esting. 
â€¢ Any subsequent AF surgery or ablation in the left atrium.   
â€¢ Any subsequent cardioversion after the [ADDRESS_657606] -ablation blanking period (treatment 
arm)/AAD optimization period (control arm) . 
â€¢ Class I or III antiarrhythmic drug (or sotalol) use after  the 90 day blanking period  (treatment arm 
only). 
The AAD optimization period is defined as the first 90 days after AAD initiation (control arm).  The 
blanking period is defined as the first 90 days after the index ablation procedure  (treatment arm) .  
Recurrences of atrial arrhythmias during the AAD optimization/blanking period s will not be counted in the 
determination of the first clinical failure for the primary endpoint.  Within the [ADDRESS_657607] shows the difference in 12 -month success rates to be less than the pre -
specified alpha of 0.05, the null hypothesis (that cryoballoon ablation has similar 12 -month efficacy rates 
compared to AAD therapy) will be rejected in favor of the alternative hypothesis (that 12 -month success 
rates for subjects treated with cryoballoon ablation is greater than for those treated with AADâ€™s),  
demonstrating the superiority of the cryo balloon ablation procedure for this endpoint.  
 Rationale for performance criteria  15.1.4.
The performance requirement for this objective involves showing superior treatment efficacy rates 
through [ADDRESS_657608] achieving success at 12 months (365 days) will be estimated using Kaplan -
Meier survival analysis.  The standard error will be approximated using Greenwoo d's formula. A two-sided 
95% log-log confidence interval for the pr obability will be constructed.  A two-sided log rank test with Î± = 
0.[ADDRESS_657609] recorded study visit date.  If treatment failure occurs on the day of index treatment, 
survival time will be set to 0.5 day s. 
If an occurrence of documented AF/AT/AFL  resulted from rhythm monitoring that was initiated at the 12 -
month visit , then th e date of occurrence used in the Kaplan -Meier analysis will be the minimum of 365 
days from the cryoballoon ablation procedure /date of AAD initiation  or the actual date of occurrence.  
This allows counting of all AF/AT/  AFL events found at the [ADDRESS_657610]  Page 84 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Sample Size  15.1.6.
Sample size assumptions are:  
â€¢ Two-sided Fisherâ€™s exact test  
â€¢ Alpha=0.0 5 
â€¢ AAD 12-month success rate = 45%  
â€¢ Cryoballoon ablation group 12 -month success rate  = 69.9%  
â€¢ Power>90% 
â€¢ Attrition from enrollment to 1 year = 10%  
The above assumptions require 87 subjects per arm with data, or 174 total subjects.  Adding in 10% 
attrition brings the overall enrollment sample size to [ADDRESS_657611] will 
be used for the primary efficacy analysis, but the more conservative Fisherâ€™s exact test was used for 
sample size estimation.  
 Determination of Patients/Data for Analysis  15.1.7.
A modified intention -to-treat protocol will be utilized for the primary efficacy analysis: all subjects for 
whom either AAD or cry oballoon ablation therapy is initiated will be analyzed according to their 
randomization status. Subjects who withdraw consent between  randomization and initiation of therapy 
will be excluded from the primary efficacy analysis. 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657612] with Î± = 0.025 : 
H0: Ps â‰¥ 12% 
Ha: Ps < 12%, 
where Ps is the probability of a safety event in subjects from the cryoballoon arm.  
 Endpoint Definition  15.2.2.
A primary safety event is defined as a serious procedure -related or cryoablation system -related adverse 
event that includes any of the following:  
â€¢ TIA within 7 days  
â€¢ Cerebrovascular accident within 7 days  
â€¢ Major bleeding that requires transfusion or results in a 20% or greater fall in hematocrit (HCT) 
within 7 days  
â€¢ Development of a significant pericardial effusion within 30 days.   A significant pericardial effusion is one that results in hemodynamic compromise, requires elective or urgent 
pericardiocentesis, or results in a 1 -cm or more pericardial effusion as documented by 
[CONTACT_51541].  
â€¢ Symptomatic PV stenosis within 12 months; accom panied by [CONTACT_080]: 50%-75% 
reduction in diameter of the pulmonary vein, with symptoms not explained by [CONTACT_39785] c onditions; 
OR >75% reduction in diameter of the pulmonary vein  
â€¢ MI within 7 days  
â€¢ PNI unresolved at 12 months  
â€¢ AE fistula within 12 months  
â€¢ Major vascular complication that requires intervention, prolongs the hospi[INVESTIGATOR_4408], or requires 
hospi[INVESTIGATOR_063] (wit hin 7 days).   
 Performance requirements  15.2.3.
If the upper bound of the two -sided 95% confidence interval of the safety event rate in cryoballoon arm 
subjects is <12%, this objective will be considered met.  
 Rationale for Performance Criteria  15.2.4.
The safety endpoint definition and performance goal ( PG) of 12%  for safety events  were based on 
previous and current Medtronic cryoballoon ablation catheter studies, as well as based on feedback from 
FDA staff.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657613]  Page 86 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 A primary safety event  rate of 3.1% was obse rved in the STOP AF trial. The 2016 Annual Report for the 
STOP AF PAS study reports a 12 month safety event rate of 2.3%. For this study , the safety event  
definition has been expanded according to FDA guidance, and certain events (e.g., symptomatic PV 
stenosis from 50 â€“ 75%, cardiac perforation/tamponade from 8 â€“ 30 days after the procedure) not 
included in the two previous studies will be included. Based on the STOP AF trial and STOP AF PAS 
adverse event data  and the expanded safety event definition, it is  estimated that the current study will 
have a safety rate of 4.0%.  
The STOP AF pi[INVESTIGATOR_508766] -Approval Study (STOP AF PAS) both set PG requirements of 
14.8%.  With an estimated 4% safety rate, a  PG of 12% provides stricter criteria  than used in prior 
cryoballoon studies, in order to account for differences in the study populations .  
Additionally, the STOP AF Pi[INVESTIGATOR_508767] 8.5% of subjectâ€™s experienced a Major Atrial Fibrillatio n Events (MAFEs) in the AAD arm (Packer et al. , 2013). A large systematic review also reported 
that withdrawals from AADs due to adverse events averaged 16.2% for Class I AADs and 11.4% for Class III AADâ€™s (Lafuente -Lafuente, Valembois, et al. 2015) . Therefore the performance criteria established in 
this study is appropriate for demonstrating an acceptable risk -benefit in this drug -naÃ¯ve PAF population.  
 Analysis Methods  15.2.5.
The probability of a safety event within 12 months will be estimated using Kaplan -Meier survival analysis. 
Greenwoodâ€™s formula will be used to approximate the standard error of the survival curve, and a two -
sided log -log confidence interval at [ADDRESS_657614] date with a corresponding CRF (i.e., the last study visit, exit date or 
death). If a subject without a safety event is lost to follow -up they will be censored on the date of the 
last study visit.  
Any subsequent ablations a subject may have after day  0 will not reset their survival time; the date of the 
index procedure will remain as day 0 for purposes of the primary safety analysis.  Safety events related to 
repeat ablation procedures occurring up to 365 days after the index cryoablation date will be considered 
as having met criteria for the primary safety endpoint, and will be counted as failures for this analysis.  
 Sample Size  15.2.6.
Sample size assumptions are:  
â€¢ One-sample, one -sided exact binomial test  
â€¢ Alpha = 0.025  
â€¢ Cryoballoon ablation 12 -month safety rate  = 4% 
â€¢ PG = 12% 
â€¢ Attrition from enrollment to 1 year = 10%   
Under these conditions, 210 enrolled subjects are required at 1:1 randomization and 10% attrition in order to expect 94 randomized and analyzable subjects at 12 -month follow -up in the cryoballoon ab lation 
arm, which affords 80% power for a one -sided binomial test with Î± = 0.025.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657615]  Page 87 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Determination of Patients/Data for Analysis  15.2.7.
All subjects randomized to the cryoablation arm and have the Arctic Front Advance Cardiac CryoAblation 
Catheter inserted into vasculature will be included.   
Subjects randomized to the AAD arm who receive a  cryoablation procedure during follow -up will not be 
included in the primary safety analysis; however, safety events occurring in these subjects will be  
reported into the study database and summari zed. 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657616]  Page 88 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 15.3. Secondary Objectives 
Two secondary objectives will be evaluated to gain additional information about the performance of the 
Arctic Front Advance Cardiac CryoAblation catheter , with four hypotheses to be t ested. 
 
Secondary Objective #1:  
Assess changes in quality of life between baseline and 12 months in the cryoballoon ablation arm.  There 
are two hypotheses tested in the objective, with separate hypothesis tests for (1) the difference in 
composite scores from the AFEQT questionnaire taken at baseline and 12 month visits, and (2) for the 
difference in composite scores for the EQ- 5D questionnaire taken at baseline and 12 -month visits.  
 
Secondary Objective #2:  
Compare health care utilization between the treatment and control arms. There are two hypotheses 
tested in the objective, with separate hypothesis tests for: (1) the rate of total health care utilization events (cardiovascular- related hospi[INVESTIGATOR_602], emergency room visits, or unscheduled office visits) over 
12 months, and (2) the rate of cardioversions (electrical or pharmacological) over 12 months.  
Testing for these objectives will be performed if the primary objectives are met. A Hochberg  multiple 
testing procedure will be utilized to maintain an overall type I error rate of 0.0 5 for the four hypotheses 
being tested among the two secondary objectives .  
The Hochberg procedure is a stepwise procedure and will be implemented as follows:   
The four hypothes es will be defined as H(1), H(2), H(3) , and H(4) . For each of the hypotheses, p -values 
will be calculated and sorted p(1) < p(2) < p(3)  < p(4). The decision rule to accept or reject each 
hypothesis will follow the step- up algorithm, where Î±= 0.05:  
Step 1: If p( 4) â‰¥ Î±, accept H( 4) and go to Step 2, otherwise reject all hypotheses and stop  
Step 2: If p( 3) â‰¥ Î±/2, accept H( 3) and go to Step 3, otherwise reject H(3), H(2) and H(1) and stop   
Step 3: if p(2) â‰¥ a/3, accept H(2) and go to Step 4, otherwise reject H(2) and H(1) and stop  
Step 4: If  p(1) < a/4, reject H(1); otherwise accept H(1)  
 Atrial Fibrillation  Effect on  Quality-of-Life (AFEQT)  15.3.1.
[IP_ADDRESS].  Hypothesis  
The following hypothesis will be tested in a two-sided test:  
 
Ho: AFEQT month12 = AFEQT baseline 
Ha: AFEQT month12 â‰  AFEQT baseline, 
Where  AFEQT baseline is the score from the AFEQT  assessed at the baseline visit , and AFEQT month12  is the 
composite score from the  AFEQT assessment from the [ADDRESS_657617]  Page 89 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  Endpoint Definition  
The AFEQT questionnaire will be utilized for this objective.  The questionnaire is an atrial fibrillation 
specific health-related quality of life questionnaire to assess the impact of AF on a subjectâ€™s life.  The 
overall score ranges from 0 â€“ 100, with [ADDRESS_657618]â€™s baseline and [ADDRESS_657619].  
[IP_ADDRESS].  Analysis Methods 
The difference in  mean AFEQT scores will be assessed utilizing a paired t- test.   
[IP_ADDRESS].  Performance Criteria  
If the p-value from the two-sample t -test procedure is less than the alpha level determined by [CONTACT_508794] , the objective will be considered met.  
[IP_ADDRESS].  Rationale for Performance Criteria  
If this analysis shows that scores from the AFEQT , a validated instrument for measuring quality of life in 
subjects with a trial fibrillation (Spertus, et al. 2011) , are significantly higher [ADDRESS_657620] will not be between randomized groups, in the context of a secondary objective that will 
only be tested if efficacy has been established, such results would provide evidence of a QoL 
improvement in cryoballoon ablation- treated patients.  
[IP_ADDRESS].   Determination of Subjects/Data for Analysis  
All subjects randomized to the cryoballoon ablation group  who have completed  both baseline and [ADDRESS_657621] a cryoballoon procedure during the 12 months of follow -up.  Having a cryoballoon procedure 
prior to 12 months will bias the AAD armâ€™s 12- month QOL results.  
[IP_ADDRESS].   Additional analyses 
The AFEQT questionnaire has three subscale scores, Daily Activities Subscale, Treatment Concern, and  
Treatment satisfaction.   Each subscale ranges from 0 â€“ 100, where 0 corresponds to low quality -of-life 
and 100 corresponds to high quality of life.  
 
Change in AFEQT subscale score is defined as 12 -month AFEQT subscale score minus baseline AFEQT  
subscale score.  A two -sided 95% confidence interval  will be calculated based on the t -distribution.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657622]  Page 90 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
   EQ-5D Questionnaire  15.3.2.
[IP_ADDRESS].  Hypothesis  
The following hypothesis will be tested in a two-sided test:  
 
Ho: EQ-5Dmonth12 = EQ-5DAAD 
Ha: EQ-5Dmonth12 â‰  EQ-5DAAD 
Where EQ-5Dmonth12 is the mean composite EQ5D score from  subjects assessed at  the 12 month visit , and 
EQ-5Dbaseline is the mean composite EQ -5D score  for at baseline . 
[IP_ADDRESS].  Endpoint Definition  
The Euroqol EQ -5D questionnaire  (which consists of a [ADDRESS_657623]â€™s overall health)  will be utilized for this objective.  Composite scores will be indexed 
against a US reference population.  (Shaw, Johnson and C oons 2004)    
[IP_ADDRESS].  Analysis Methods  
Change in EQ-5D composite score is defined as [ADDRESS_657624]. A two -sided 
95% confidence interval will be calculat ed based on the t -distribution. 
[IP_ADDRESS].  Performance criteria  
If the p-value from the paired t-test is less than the alpha level determined by [CONTACT_508795] , the objective will be considered met.  
[IP_ADDRESS].  Rationale for Perfo rmance Criteria  
If this analysis shows that EQ -5D scores are significantly higher after 12 -months follow -up compared to 
baseline in cryoballoon -treated subjects, it will provide evidence of an association between cryoballoon 
ablation and a general  QoL incr ease (as measured by a validated instrument)  that may or may not be 
causal. While this hypothesis test will not be between randomized groups, in the context of a secondary 
objective that will only be tested if efficacy has been established, the evidence pr ovided is stronger than 
if it were just performed in an isolated pre -post comparison.  
[IP_ADDRESS].  Determination of Subjects/Data for Analysis  
All cryoballoon ablation arm  subjects who  have completed both baseline and [ADDRESS_657625] a cryoballoon procedure during the 12 months of follow -up.  Having a cryoballoon procedure 
prior to 12 months will bias the AAD armâ€™s 12- month QoL results.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657626]  Page 91 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Cardiovascular hospi[INVESTIGATOR_602], ED and unscheduled office visits  15.3.3.
[IP_ADDRESS].  Hypothesis  
The following hypothesis will be tested . 
 H 0: Î¸cryo = Î¸AAD 
 Ha: Î¸cryo â‰  Î¸AAD, 
where Î¸ cryo and Î¸ AAD are the 12 -month rates of cardiovascular  HCU events in the cryoballoon ablation and 
AAD arms, respectively.  
[IP_ADDRESS].  Endpoint Definition  
Healthcare utilization (HCU) events for this objective  are defined as cardiovascular -related 
hospi[INVESTIGATOR_602], cardiovascular- related emergency department  visits, or cardiovascular -related 
unscheduled office visits occurring within 12 months  after the index ablation (cryo arm) or the initiation 
of therapy (AAD arm).  Events occurring >365 days after initiation of treatment but before the 12 -month 
visit will be included.   
[IP_ADDRESS].  Analysis Methods 
The probability of a subject achieving freedom from HCU events (defined above) at [ADDRESS_657627] error will be approximated using 
Greenwood's formula. A two-sided 95% log -log confidence interval for the probability at [ADDRESS_657628] known 
study visit date.  For HCU events occurring  on the day of index treatment, survival time will be set to 0.5 
days. 
The survival curve from 0 to 12 months will be presented for both treatment arms. HCU events will also 
be summarized by [CONTACT_508796].  
[IP_ADDRESS].  Performance Requirements  
If the p-value from two-sided log -rank test is less than the alpha level determined by [CONTACT_508797], the objective will be considered met. 
[IP_ADDRESS].  Rationale for Performance Requirements  
If the test specified above indicates a statistically significant increase in the time to the first HCU event 
between cryoballoon ablation and AAD -treated subjects, this is sufficient evidence to say that the 
treatment has a lower rate of healthcare utilization  within a year of treatment initiation, due to the 
randomized and intention -to-treat nature of the comparison.   
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657629]  Page 92 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  Determination of Subjects/Data for Analysis  
The modified intent -to-treat cohort will be utilized.  All subjects who initiate either AAD therapy or 
cryoballoon ablation will be analyzed according t o the group to which they were randomized.  
 Cardioversions  15.3.4.
[IP_ADDRESS].  Hypothesis  
The following hypothesis will be tested with a two- sided test.   
 H 0: Î³cryo = Î³AAD 
 Ha: Î³cryo â‰  Î³AAD, 
where Î³cryo and Î³AAD are the 12 -month rates of cardioversion (either electrical or pharmacological)  in the 
cryoballoon ablation and AAD arms, respectively.  
[IP_ADDRESS].  Endpoint Defin ition 
A cardioversion event is defined as an electrical or pharmacological cardioversion  post index ablation 
discharge for the treatment arm, and post AAD initiation for  the AAD arm  
[IP_ADDRESS].  Analysis Methods  
The probability of a subject achieving freedom from cardioversion (defined above)  at 12 months (365 
days) will be estimated using Kaplan -Meier survival analysis.  The standard error will be approximated 
using Greenwood's formula. A two- sided 95% log -log confidence interval for the pr obability at [ADDRESS_657630] known study visit date.  For cardioversions occurring  on the day of index treatment, 
survival time will be set to 0.5 day s. 
The survival curve from 0 to 12 months will be p resented for both treatment arms. Counts of all 
cardioversions administered over 12 months will also be summarized.  
[IP_ADDRESS].  Performance Requirements   
If the p-value from two-sided log -rank test is less than the alpha level determined by [CONTACT_508798], the objective will be considered met.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657631]  Page 93 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  Rationale for Performance Criteria  
If the test specified above indicates a statistically significant increase in the time to the first cardioversion 
between cryoballoon ablation and AAD -treated subjects, this is sufficient evidence to say that the 
treatment has a lower rate of cardioversions within a year of treatment initiation, due to the randomized 
and intention -to-treat nature of the comparison.  
[IP_ADDRESS].  Determination of Subjects/Data for Analysis  
The modified intent -to-treat cohort will be utilized.  All subjects who initiate either AAD therapy or 
cryoballoon ablation will be analyzed according to the group to which they were randomized in the 
assessment of this objective.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657632]  Page 98 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 16. Ethics 
16.1. Statement (s) of Compliance   
The study will be conducted in compliance with international ethical and scientific quality standards,  
known as good clinical practice (GCP). GCP includes review and approval by [CONTACT_508799] (IRB)/ Ethics Committee (EC) befor e initiating a study, continuing review of an ongoing 
study by [CONTACT_2717]/EC, and obtaining and documenting the freely given informed consent of a subje ct 
before initiating the study.  
 
The study was designed to reflect the GCP principles outlined in ISO 141 55:[ADDRESS_657633], monitor, any Investigator(s) or 
other parties participating in or contributing to the  clinical investigation. All Investigators shall avoid 
improper influence on or inducement of the subject, sponsor, monitor, other Investigator(s) or other 
parties participating in or contributing to the clinical investigation. The ISO standard also inform ed study 
design in the areas of device deficiency reporting and risk evaluation, with t he exception (to Section 6.[ADDRESS_657634]) that only those Adverse Events (AEs) which are cardiovascular related, serious 
(regardless of relatedness), AAD related , cryoablation system related and/or procedure related  will be 
collected. This ensures any AEs which could potentially be relevant will be collected. There is a second 
exemption (to Section 18.[ADDRESS_657635]) that device accountability will not b e performed in 
Europe and only upon package opening in the US.  
 The study will be conducted according to  the CIP,  federal, national and local laws, regulations, standards, 
and requirements of the countries/geographies where the study is being condu cted. In E urope, the study 
will also be conducted in accordance with the Declaration of Hels inki 2013. For all geographies, the 
principles of the Declaration of Helsinki have been implemented through the patient informed consent (IC) process, IRB/EC approval, study training, clinical trial registration, preclinical testing, risk -benefit 
assessment and publication policy.  
 Ultimately, all centers in all geographies will follow and comply with:  
 
â€¢ Principles of Declaration of Helsinki (including privacy and data protection laws), or the laws and  
regulations of each participating country, whichever affords greater protection for the study  
subjects 
â€¢ 21 CFR Part 11 (Electronic Records, Electronic Signatures)  
â€¢ 21 CFR Part 54 (Financial Disclosure by [CONTACT_6230])  
â€¢ The procedures described with in this CIP  
â€¢ Local Ethics Board requirements  
 
All participating geographies will make study data available to the  regulatory body such as FDA or 
competent authority if the regulatory body deems an onsite inspection nece ssary. The r egulatory body 
will be able to inspect records at clinical centers around the world to resolve any uncertainties about 
whether the study was conducted in accordance with good clinical practice.  
 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657636]  Page 99 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 In addition to the regulatory requirements outlined above, th e study will be conducted in compliance with 
relevant local laws. These include but are not limited to:  
 
â€¢ In the [LOCATION_002], US FDA 21 CFR Parts  
o 50: Protection of Human subjects,  
o 56: Institutional Review Boards  
o 812: Investigational  Device Exemptions  
â€¢ In Europe, Declaration of Helsinki 2013, the Competent Authority requirements, the Medical 
Device Directive (MDD) 93/42/EEC and ISO [ZIP_CODE]:[ADDRESS_657637] (FDAAA) and Declaration of Helsinki on ht tp://clinicaltrials.gov (PL 110 
85, Section 810(a)).  
 
Approval of the Clinical Investigation Plan (CIP) is required from the following groups prior to any study  
procedures at a study center: 
 
â€¢ US Food and Drug Administration (FDA) or regulatory authority  
â€¢ Medtronic  
â€¢ Principal Investigators (where required by [CONTACT_1769])  
â€¢ An independent  IRB/EC 
 Similarly, approval of subsequent revisions to the CIP is required at each study center from the above  
mentioned groups prior to implementation of the revised CIP at that center.  
 Medtronic maintains appropriate clinical study liability insurance coverage as required under applicable 
laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage.  If required, a clinical insurance statement/certificate will be provided to the IRB/EC. 
The study is conducted in multiple countries, therefore reimbursement and indemni fication will be 
addressed on a country specific basis in the study documents and center Clinical Trial Agreements.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657638]  Page 100 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 17. Study Administration  
17.1. Role of the Sponsor Representatives  
Sponsor representatives may provide support as required for the study under super vision of the Principal 
Investigator, including:  
â€¢ Provide study training relevant and pertinent to the involvement of personnel conducting study 
activities and investigator responsibilities  
â€¢ Technical support at the ablation procedure  under the supervision of a study investigator, but no 
data entry, shall be performed by [CONTACT_389403]  
â€¢ Monitoring and auditing activities  
17.2. Monitoring  
It is the responsibility of Medtronic to ensure proper monitoring of this clinical study.  Trained Medtronic  
personnel or delegates appointed by [CONTACT_508800], the Clinical Trial Agreement, and 
applicable regulatory and local requirements.   Medtronic, or delegates, must therefore be allowed  direct 
access to the  subjectsâ€™ case histories (clinic and hospi[INVESTIGATOR_1097], and other source data/doc umentation) 
upon request as  per the IC Form, Research Authorization (where applicable) and Clinical Trial Agreement.  
The Principal  Investigator [INVESTIGATOR_131437].  
Frequency  of monitoring  visits will occur based on subject enrollment,  duration of the study, study 
compliance,  number of adverse events, number of deviations,  findings from previous monitoring  visits and 
any suspected inconsistency in data that requires investigation.   Regulatory  documents  (e.g., IRB/EC 
approval  letters, etc.) may be reviewed  at each study center.  Monitoring for the study may include, but 
are not limited to, site initiation visits, interim monitoring visits, and closeout visits, and will be done in 
accordance with the study -specific monitoring plan.  The extent of source data verification will be 
specified in the study -specific monitoring plan.  
Monitoring  visits will be conducted  periodically to assess site study progress, the investigatorâ€™s adherence  
to the Clinical Investigation Plan, regulatory  compliance  including  but not limited to IRB/MEC  approval  and 
review of the study, maintenance  of records and reports, and review of source documents  against subject 
CRFs and for unreported adverse events .  Monitors  facilitate site regulatory  and study compliance by 
[CONTACT_508801]-compliance  and communicating  those findings along with recommendations  for 
preventative/corrective  actions to site personnel.  Findings and non -compliance will also be communicated 
to study personnel via a monitoring follow -up letter.   Monitors  may work with study personnel  to 
determine appropriate  corrective  action recommendations  and to identify trends within the study or at a 
particular center. 
17.3. Data Management  
Data will be collected via an electronic data management  system for clinical studies. CRF data will be 
stored in a secure, password -protected  database  which will be backed up nightly. Data will be reviewed  
using programmed and manual data checks.  Data queries will be made available to centers for resolution.   
The Investigator must approve the completed CRFs and the Investigator, or authorized designee, must 
complete CRFs and make CRF corrections.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657639]  Page 101 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Data collected by a mbulatory monitoring  and 12-lead ECGs will be managed and over- read by a core  lab.  
Final classification of recurrent AF/AT/AFL will be store d in the study database.  
Study management  reports may be generated  to monitor data quality and study progress.  At the end of 
the study, the data will be frozen and will be retained indefinitely by [CONTACT_13735].  
All records and other information about subjects participating in this study will be treated as confidential. 
Data will be transferred and processed by [CONTACT_13757] a third party designated by [CONTACT_54452] a key 
coded form, unless itâ€™s impossible to make it anonymous, for instance, where the subjectâ€™s name [CONTACT_446180] , such as fluoroscopy images.  In the case that de -identifying is 
impossible or involves a disproportionate effort, files containing personal data of subjects shall only be made accessible to authorized pe rsons (secured role -based access) . 
17.4. Direct Access to Source Data/Documents  
The sponsor or a regulatory authority may audit or inspect the study site to evaluate the conduct of the 
study.  The clinical investigator(s)/institution(s) shall allow study relate d monitoring, audits, IRB review 
and regulatory inspection by [CONTACT_20618]/documents.   If direct access is not 
feasible, certified copi[INVESTIGATOR_508768] . 
17.5. Confidentiality  
All records and other information about subjects participating in this study will be treated as confidential. See sections 17.3 and 17.4 for further information.
 
17.6. CIP Amendments  
Approval of subsequent revisions to the CIP is required at each study center from the following groups 
prior to implementation of the revised CIP at the center:  
â€¢ Medtronic 
â€¢ Principal Investigators (where required by [CONTACT_1769])  
â€¢ Geography -specific regulatory authorities (if regulatory approval is required)  
â€¢ An independent EC or IRB  
If a CIP amendment occurs, center personnel will need to be re- trained as necessary, and wil l need to 
submit any changes to their IRB/EC as required by [CONTACT_942].  CIP amendments will also be reported 
to and approved by [CONTACT_1622].  
17.7. Record Retention  and Reports  
Medtronic records and reports will be maintained in a password- protected document mana gement 
system, and paper documents (where applicable) will be stored in stored in secured file cabinets at 
Medtronic d uring the course of this study.  
After closure of the study Medtronic will archive records and reports indefinitely.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657640]  Page 102 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Investigator Records  17.7.1.
The investigator is responsible for the preparation  and retention  of the records cited below.  All of the 
below records, with the exception  of case history records and case report forms, should be kept in the 
Investigator Site File (i.e., the study binder provided  to the investigator) or Subject Study Binder. CRFs 
may be maintained and signed electronically within the electronic data capture system during the trial.  
The following records are subject to inspection and must be retained for a period of two years (or longer 
as local law or hospi[INVESTIGATOR_508769]) after the date on which the investigation is terminated.  
â€¢ All correspondence  between  the IRB/EC, sponsor, monitor, FDA and/or other regulatory  bodies, 
and/or the investigator that pertains to the investigation, including  required reports 
â€¢ Subjectsâ€™  case history records, including:  
o Signed and dated Informed  Consent Form 
o Observations of adverse events/adverse  device effects 
o Medical history 
o Procedure  and follow-up data 
o Documentation  of the dates and rationale  for any deviation from the protocol 
â€¢ Reports of Adverse Events  
â€¢ Signed and dated CRFs 
â€¢ Blank case report forms (Europe only)  
â€¢ Su
bject screening logs (if used)  and subject identification logs (Europe only)  
â€¢ Randomization list  
â€¢ List of investigation  centers 
â€¢ All approved  versions of the CIP, ICF, and Investigatorâ€™s Brochure/Report of Prior Investigation 
Summary  
â€¢ Signed and dated Clinical Trial Agreement  and Investigator Statement 
â€¢ Financial Disclosure of Investigators 
â€¢ Current curriculum  vitae (signed and dated in Europe)  of all participating Investigators  and key  
members of investigation center team (Europe only)  
â€¢ Documentation of delegated tasks  
â€¢ IRB/EC approval  documentation  including  written information that the investigator or other 
study staff, when member of the IRB/EC, did not participate in the approval  process. 
Approval documentation must include the IRB/EC composition, in Europe and where required 
by [CONTACT_1769].  
â€¢ Regulatory authority notification, correspondence and approval, where required by [CONTACT_1769].  
â€¢ Study training records for center staff 
â€¢ Insurance certificates (where required by [CONTACT_1201]/EC)  
â€¢ Any other records that FDA or regulatory  authorities require to be maintained  
â€¢ Final Report of the clinical investigation  prepared and distributed by [CONTACT_456] 
â€¢ Final Investigator R eport prepared  by [CONTACT_508802] 
â€¢ Final Clinical Study Report, including the statistical analysis  
 Investigator Reports  17.7.2.
The Investigator is responsible for the preparation (review and signature) and submission to the sponsor 
of all case report forms, adverse events, device deficiencies, deaths, and any deviations from the clinical 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657641]  Page 106 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 â€¢ All approved versions of the Clinical Investigation Plan and study related reports, 
Investigatorâ€™s Brochure/Report of Prior Investigation Summary  
â€¢ All case report forms and supporting  documentation  submitted by [CONTACT_1697], samples of 
Informed Consent Forms, and other information  provided  to the subjects 
â€¢ Copi[INVESTIGATOR_28078]/EC approval  letters and relevant IRB/EC correspondence and 
IRB/EC voting list/roster/letter of assurance  
â€¢ Names of the institutions in which the clinical investigation  will be conducted  
â€¢ Regulatory authorities correspondence, notification and approval, as required by [CONTACT_169294] 
â€¢ Insurance certificates  
â€¢ Randomization List  
â€¢ Names/contact [CONTACT_54459]  
â€¢ Monitoring visit reports and follow -up letters  
â€¢ Forms for reporting any adverse events and adverse device effects 
â€¢ Statistical analyses and underlying  supporting  data. 
â€¢ Final report of the clinical investigation 
â€¢ Study training records for center personnel  and Medtronic  personnel  involved in the study 
â€¢ Any other records that local regulatory  agencies  require to be maintained 
 Sponsor Reports  17.7.4.
Medtronic shall prepare and submit the following complete, accurate, and timely reports listed in the 
tables below  (by [CONTACT_13736]).  In addition to the reports listed below, Medtronic shall, upon request of 
reviewing IRB /EC, regulatory agency or FDA, provide accurate, complete and current information about 
any aspect of the investigation. Safety data reporting requirements are listed in the adverse event section. 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657642]  Page 111 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 The publication committeeâ€™s role is to:  
â€¢ Manage elements addressed in the publication plan,  
â€¢ Develop the final publication plan under separate cover,  
â€¢ Execute the publication plan,  
â€¢ Oversee the publication of primary, secondary  study results,  
â€¢ Review and prioritize publication propo sals,  
â€¢ Provide input on publication content,  
â€¢ Determine authorship,  
â€¢ Ensure the International Committee of Medical Journal Editors (ICMJE) quality and rules guidance 
is used, and  
â€¢ Determine procedure for documentation of decisions related to the generation  of publications.  
In addition, the committee will apply and reinforce the authorship guidelines set forth in the publication 
plan.  Membership in the publication committee does not guarantee authorship.  The committee will meet 
at as needed.  
 Management of Primary, Secondary and Ancillary Publications  17.8. 1.
The publication committee reviews, prioritizes, and manages all publications including primary, secondary and ancillary publications.  Primary and secondary publications are those that address analyses of any o r 
all prim 
ary objectives or secondary objectives, respectively, as specified in the clinical investigation plan.  
An anc
illary publication is any publication that does not address the study objectives identified in the 
clinical investigation plan.  They inc lude publications proposed and developed by [CONTACT_181031], clinicians participating in this clinical study, and clinicians not participating in this clinical study.  The committee will work with Medtronic to ensure that requests do not present conflicts 
with other proposals, are not duplicative, and to determine which ancillary publication proposa ls, if any, 
will be supported.  
The committee may decide that no publications, including abstracts, will be published prior to the end of the study or with individual center data.  Requests for publications on study objectives utilizing subset 
data (e.g., regional) will be evaluated for scientific validity and the ability of Medtronic to pro vide 
resources.  
 Criteria for Determining Authorship  17.8.2.
Publications will adhere to authorship criteria defined by [CONTACT_4717] (ICMJE, Uniform requirements for manuscripts submitted to biomedical journals, www.icmje.org).  
Individual authorship criteria defined by [CONTACT_508803].  
Decisions regarding authorship and contributor -ship will be made by [CONTACT_942]. The selected authors 
will be responsible for drafting the publication.  All selected authors must fulfill the authorship conditions 
stated above to be listed as authors, and all contributors who fulfill the conditions must be listed as 
authors. 
All investigators not listed as co -authors will be acknowledged as the â€œ STOP AF First Study Investig atorsâ€ 
and will be individually listed according to the guidelines of the applicable scientific journal when possible 

056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657643]  Page 112 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 and affiliation.  Any other contributors will be acknowledged by [CONTACT_508804]. 
 Transparency  17.8.3.
Transparenc y of study results will be maintained by [CONTACT_54465]:  
â€¢ A final report, describing the results of all objectives and analysis, will be distributed to all 
investigators and IRBs  
â€¢ Registering and posting the study results on ClinicalTrials.gov based on the posting rules 
stipulated 
â€¢ Submitting for publication the primary stu dy results after the study ends  
â€¢ Disclosing conflicts of interest (e.g., financial) of the co -authors of publications according to the 
policies set forth by [CONTACT_54466]  
â€¢ Making an individual centerâ€™s study data accessible to the corresponding investigator after the completion of the study, if requested  
17.9. Suspension or Early Termination  
 Planned Study Closure  17.9.1.
Study closure is a process initiated by [CONTACT_57661] a study closure letter.  Study closure is defined as 
closure of a clinical study that occurs when Medtronic and/or regulatory requirements have been satisfied 
per the CIP and/or by a decision by [CONTACT_131488], whichever occurs first.  The study 
closure process is complete upon distribution of the final report or after final payments, whichever occurs last.  Ongoing IRB/EC oversight is required until the overall study closure process is complete. Refer to 
sections 11.5.13 and 11.10 for additional information regarding study exit procedures.  
 Early Terminati on or Suspension  17.9.2.
Early termination is the closure of a clinical study that occurs prior to meeting defined endpoints. This is 
possible for the whole study or a single site.  Study suspension is a temporary postponement of study 
activities related to enrollment.  This is possible for the whole study or a single site.  
 Study-wide termination or suspension  17.9.3.
Possible reasons for considering study suspension or termination of the study include but are not limited to: 
â€¢ Decision by [CONTACT_54467] (where  the study is operating u nder regulatory body 
authority)  
â€¢ Adverse events associated with the system or product under investigation which might endanger 
the safety or welfare of the subject 
â€¢ Observed/suspected performance different from the productâ€™s design i ntent 
â€¢ Enrollment is slower than anticipated  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657644]  Page 113 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  Site termination or suspension  17.9.4.
Possible reasons for clinical investigator or site termination or suspension include but are not limited to:  
â€¢ Failure to obtain initial IRB approval or annual renewal of the study  
â€¢ Persistent non -compliance to the clinical investigation  
â€¢ Lack of enrollment  
â€¢ Noncompliance to regulations and the terms of the CTA (e.g. failure to submit data in a timely 
manner, failure to follow -up on data queries and monitoring findings in a timely manner)  
â€¢ IRB/EC suspension of the site  
â€¢ Fraud or fraudulent misconduct is discovered (as defined by [CONTACT_54468])  
â€¢ Investigator request (e.g., no longer able to support the study)  
 Procedures for Termination or Suspension  17.9.5.
[IP_ADDRESS].  Medtronic -initiated and regulatory authority -initiated  
â€¢ Medtronic will promptly inform the clinical inve stigators of the termination or suspension and the 
reasons and inform the regulatory authority where required  
â€¢ In the case of study termination or suspension for reasons other than a temporary IRB/EC 
approval lapse, the investigator will promptly inform the  IRB/EC and the institution (where 
required per regulatory requirements)  
â€¢ In the case of study termination, the investigator must inform the subjects (or legally authorized designees or guardians, US ONLY ), and may inform the personal physician of the subje cts to 
ensure appropriate care and follow -up is provided  
â€¢ In the case of a study suspension, subject enrollment must stop until the suspension is lifted by [CONTACT_13735]  
â€¢ In the case of study suspension, enrolled subjects should continue to be followed out of consideration of their safety, rights and welfare  
[IP_ADDRESS].  Investigator -initiated  
â€¢ The Investigator will inform Medtronic and provide a detailed written explanation of the 
termination or suspension  
â€¢ The Investigator will promptly inform the institution (where require d per regulatory 
requirements)  
â€¢ The Investigator will promptly inform the IRB /EC and regulatory authority (where required per 
regulatory requirements)  
â€¢ The Investigator will promptly inform the subjects, and may inform personal physician of the 
subjects to ensure appropriate care and follow -up is provided  
â€¢ In the case of study suspension, enrolled subjects should continue to be followed out of consideration of their safety, rights and welfare  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657645]  Page 114 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 [IP_ADDRESS].  IRB/EC-initiated  
â€¢ The Investigator will inform Medtronic and provide  a detailed written explanation of the 
termination or suspension within 5 business days  
â€¢ Subject enrollment must stop until the suspension is lifted 
â€¢ Subjects already enrolled should continue to be followed in accordance with IRB policy or its 
determination that an overriding safety concern or ethical issue is involved  
â€¢ The Investigator will inform his/her institution (where required per local requirements)  
â€¢ The Investigator will promptly inform the subjects (or legally authorized designees or guardians, 
except in Europe),  and may inform the personal physician of the subjects, with the rationale for 
the study termination or suspension  
â€¢ The Investigator will inform local regulatory authority, where required per regulatory 
requirements  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657646] Antiarrhythmic Drug Substudy Investi. "Maintenance of sinus rhythm in patients with atrial 
fibrillation: an AFFIRM substudy of the first antiarrhythmic drug." J Am Coll Cardiol  42 (2003): 
20-9. 
Arena, G,  C Tondo, G Cattafi, and et. al. "Cryoballoon ablation as treatment of recent paroxysmal atrial 
fibrillation. Data from a large cohort of patients followed in a real world multicenter experience." 
Heart Rhythm  13 (2016): S375 -76. 
Calkins, et. al. "HRS/EHRA /ECAS expert Consensus Statement on catether and surgical ablation of AF; 
recommendations for patient selection, procedural techniques and follow -up, definitions, 
endpoints, and research trial design. A report of the HRS task force..." Heart Rhythm  9, no. 4 
(2012): 632- 696.e20.  
Caulkins, H, and et. al. . "HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical 
Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow -Up." 
Europace  9, no. 6 (2007): 335 -379. 
Cosio, FG, E Aliot, GL Botto, and et. al. . "Delayed rhythm control of atrial fibrillation may be a cause of 
failure to prevent recurrences: reasons for change to active antiarrhymic treatment at the time of 
the first detected epi[INVESTIGATOR_1865]." Europace  10 (2008): 21-7. 
De Vos, CB, R Pi[INVESTIGATOR_9698], R Nieuwlaat, and et. al. . "Progression from paroxysmal to persistent atrial 
fibrillation clinical correlates and prognosis." J Am Coll Cardiol  55 (2010): 725- 31. 
Go, A, E Hylek, K Phillips, and et. al. "Prevalence of Diagnosed Atrial Fibrillation in Adults: National 
Implications for Rhythm Management and Stroke Prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study." 
JAMA 285, no. 18 (2001): 2370 -2375. 
Hommel, G. "A stagewise rejective multiple test procedure based on a modified Bonferroni test." 
Biometricka  75 (1988): 383 -386. 
Jais, P, MD O'Neill, Y Takahashi, and et. al. . "Stepwise Catheter Ablation of Chronic Atrial Fibrillation: 
Importance of Discrete Anatomic Sites for Termination." J Cardiovasc Electrophysiol  17, no. 
Suppl. 3 (2006): S28- S36. 
Jalife, J, and K Kaur. "Atrial remodeling, fibrosis, and atrial fibrillation." Trends Cardiovasc Med  25 (2015): 
475-84. 
January, CT, and et. al. . "2014 AHA/ACC/HRS Guideline for the Management of Patients w ith Atrial 
Fibrillation." JACC 64, no. 21 (2014): e1- 76. 
January, CT, et al. "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: 
Executive Summary." Journal of the American College of Cardiology , 2014. 
Knight, BP, PG Novak,  R Sangrigoli, and et. al. "Second generation cryoballoon: results from the 
multicenter STOP AF Post Approval Study 12 -month clinical outcomes following pulmonary vein 
isolation using the Arctic Front Adfance." Cardiostim (abstract).  2016. 
Kuck, KH, et al.  "Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation." N Engl J Med  
374 (2016): 2235- 45. 
Lafuente -Lafuente, C, L Valembois, JF Bergmann, and J Belmin. "Antiarrhythmics for maintaining sinus 
rhythm after cardioversion of atrial fibrillation." Cochrane Database of Systematic Reviews , 2015. 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657647]  Page 116 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Lafuente -Lafuente, C, S Mouly, MA Longas -Tejero, and et. al. "Antiarrhythmic drugs for maintaining sinus 
rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled  
trials." Arch Intern Med  166 (2006): 719- 28. 
Morillo, CA, A Verma, SJ Connolly, and et. al. "Radiofrequency ablation vs. antiarrhythmic drugs as first -
line treatment of paroxysmal atrial fibrillation (RAAFT -2): A randomized trial." JAMA 311, no. 7 
(2014): 692-700. 
Nattel, S, E Guasch, I Savelieva, and et. al. "Early management of atrial fibrillation to prevent 
cardiovascular complications." Eur heart J  35 (2014): 1448 -56. 
Nielsen, JC, et al. "Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation." New 
England Journal of Medicine , October 25, 2012: 1587 -96. 
Oral, H, BP Knight, H Tada, and et. al. . "Pulmonary vein isolation for paroxysmal and persistent atrial 
fibrillation." Circulation  105 (2002): 1077 -81. 
Packer, D, et al. "CryoBalloon ablation: first results of North America STOP AF pi[INVESTIGATOR_16076]." J Am Coll 
Cardiol 61, no. 16 (2013): 1713- 1723. 
Raviele, et. al. . "Venice Chart International consensus document on atrial fibrillation: 2011 Update." J 
Cardiovasc Electrophysiol  23 (2012): 890 -923. 
Romero, J, C Gianni, L Di Biase, and A Natale. "Catheter ablation for long -standing persistent atrial 
fibrillation: On -treatment analysis of the randomized con trolled MANTRA -PAF trial." Int J Cardiol J  
11 (2015): 87 -93. 
Shaw, JW, JA Johnson, and SJ Coons. "U.S. Valuation of the EQ -5D Heatlh States: Development and 
Testing of the D1 Valuation Model." Medical Care , 2004. 
Shulka, A, and AB Curtis. "Avoiding permane nt atrial fibrillation: treatment approaches to prevent disease 
progression." Vasc Health Risk Manag  10 (2014): 1- 12. 
Spertus, J, et al. "Development and validation of the Atrial Fibrillation Effect on Quality -of-Life (AFEQT) 
Questionnaire in patients with  atrial fibrillation." Circ Arrhythm Electrophysiol , Feb 4, 2011: 15 -
25. 
Tanner, H, K Makowski, L Roten , and et. al. "Catheter ablation of atrial fibrillation as first -line therapy - a 
single-center experience." Europace  13 (2011): 646 -53. 
Walters, TE, A N isbet, GM Morris, and et. al. "Progression of atrial remodeling in patients with high -
burden atrial fibrillation: Implications for early ablative intervention." Heart Rhythm  13 (2016): 
331-9. 
Wazni, OM, et al. "Radiofrequency Ablation vs. Antiarrhythmic Dr ugs as First -Line Treatment of 
Symptomatic Atrial Fibrillation." JAMA, June 1, 2005: 2634 -40. 
Wijesurendra, RS, and B Casadei. "Atrial fibrillation: effects beyond the atrium?" Cardiovasc Res  105 
(2015): 238- 47. 
Wolf, P, R Abbott, and W Kannel. "Atrial fib rillation as an independent risk factor for stroke: the 
Framingham Study." Stroke 22, no. 8 (1991): 983-988.  
Wu, J-H, H-K Li, DM Couri, and et. al. "Reversal of pulmonary vein remodeling after catheter ablation of 
atrial fibrillation." J Geriatr Cardiol  13 (2016): 163- 8. 
 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657648]  Page 119 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
  
Appendix B: DRAFT DATA COLLECTION ELEMENTS (CASE REPORT FORMS)  
Draft Case Report Forms for the STOP AF First study  will be provided under separate cover.  Final CRFs 
will be provided to study centers via the electronic data management system after the center has fulfilled 
all requirements for database access.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657649]  Page 120 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Appendix C: INFORMED CONSENT FORM TEMPLATE  
The Informed Consent  Form Template will be distributed under separate cov er. 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657650]  Page 121 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Appendix D: PARTICIPATING INVESTIGATOR AND INSTITUTIONS  
A final list of participating Investigators and institutions has not been finalized prior to development of the 
Clinical Investig ation Plan and will be distributed  under separate cover.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657651]  Page 122 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Appendix E: IRB LIST  
A final IRB list has not been finalized prior to development of the Clinical Investiga tion Plan and will be 
distributed under separate cover. 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657652]  Page 123 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Appendix F: FORESEEABLE ADVERSE EVENTS  
The information provided in this section pertains to foreseeable adverse events that may be observed in 
study subjects and may collectively assist in identifying those events for a given device or therapy that 
are unexpected in nature.  The foreseeable adverse events information consists of two parts: a listing of potential adverse events associated with cryoablation therapy/procedure and adverse event rates 
reported in published literature for sa me therapy/procedure (see Appendix A).  An evaluation of 
potentially anticipated events and reported events in literature may be used in combination w ith device 
labeling/IFU, current event reporting information, and other published data to assess for an unexpected 
occurrence.  
The cryoablation procedure involves surgery, therefore, standard adverse events associated with a 
surgical procedure may be experienced (e.g. anesthesia complications, injury, infections, bleeding, 
exacerbation of pre -existing conditions, healing complications, etc.). The  focus of this section is to 
specifically address in more detail, those events that are foreseeable due to the use, performance, and/or presence of the Arctic Front Advance â„¢ CryoAblatio n Catheter under investigation.  
Additional potential risks associated w ith the Arctic Front Advance â„¢ CryoAblation Catheter, as well as risk 
minimization are discussed within section 12. 
Treatment required for procedure and/or cryoablation system related adverse events that are 
experienced may include medication or other surgical and medical remedies. The adverse events associated with the use of the Arctic Front Advance â„¢ CryoAblation Catheter include but are not limited to 
those in Table 14 and Table 15. 
Table 14 pertains to the foreseeable/anticipated adverse events that may be observed in the study and 
may assist in identifying those adverse events that are unexpected in nature.  
Table 14: Foreseeable Adverse Events  
Anemia Feeling cold  Pseudoaneurysm  
Anxiety Fever Pulmonary edema  
Arrhythmia  Gastrointestinal 
discomfort  Pulmonary embolism  
Arteriovenous fistula  Gastroparesis Pulmonary 
hemorrhage  
Atrial fibrillation  Headache  Pulmonary 
hypertension  
Atrial flutter  Heart block  Pulmonary infarction  
Atrio-esophageal fistula  Heart failure  Pulmonary infiltration 
Back pain  Hematemesis  Pulmonary vein 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_657653]  Page 128 of 128 
10APR2017 Clinical Investigational  Plan 
 Medtronic Confidential   
 Appendix G: PRE-CLINICAL TESTING  
A summary of results from pre -clinical testing with the Arctic Front Advance â„¢ Cardiac CryoAblation 
Catheter is provided in the Report of Prior Investigations Summary.  
 